drug1_db stringlengths 7 7 | drug2_db stringlengths 7 7 | drug1_id int64 0 1.69k | drug2_id int64 0 1.69k | drug_pair listlengths 2 2 | drug1_name stringlengths 4 85 | drug2_name stringlengths 4 85 | drug1_desc stringlengths 27 1.09k | drug2_desc stringlengths 27 6.14k | label stringclasses 3
values | label_idx int64 0 2 | all_paths listlengths 1 10 | all_paths_str listlengths 1 10 | path_str stringlengths 0 3.57k |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
DB00242 | DB00888 | 1,064 | 1,001 | [
"DDInter392",
"DDInter1133"
] | Cladribine | Mechlorethamine | An antineoplastic agent used in the treatment of lymphoproliferative diseases including hairy-cell leukemia. | A vesicant and necrotizing irritant destructive to mucous membranes, mechlorethamine is an alkylating drug. It was formerly used as a war gas. The hydrochloride is used as an antineoplastic in Hodgkin's disease and lymphomas. It causes severe gastrointestinal and bone marrow damage. The FDA granted marketing approval f... | Major | 2 | [
[
[
1064,
25,
1001
]
],
[
[
1064,
25,
450
],
[
450,
1,
1001
]
],
[
[
1064,
5,
11555
],
[
11555,
44,
1001
]
],
[
[
1064,
21,
30038
],
[
300... | [
[
[
"Cladribine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Mechlorethamine"
]
],
[
[
"Cladribine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cyclophosphamide"
],
[
"Cyclophosphami... | Cladribine may lead to a major life threatening interaction when taken with Cyclophosphamide and Cyclophosphamide (Compound) resembles Mechlorethamine (Compound)
Cladribine (Compound) treats hematologic cancer (Disease) and hematologic cancer (Disease) is treated by Mechlorethamine (Compound)
Cladribine (Compound) caus... |
DB00781 | DB00994 | 1,481 | 361 | [
"DDInter1489",
"DDInter1277"
] | Polymyxin B | Neomycin | Polymyxin B was discovered in the 1940s. They are basic polypeptides of about eight amino acids and have cationic detergent action on cell membranes. Polymyxin B is used for infections with gram-negative organisms, but may be neurotoxic and nephrotoxic[A176426,FDA Label]. All gram-positive bacteria, fungi, and the gram... | Neomycin is a broad-spectrum aminoglycoside antibiotic drug that is derived from the metabolic products of _Streptomyces fradiae_. Neomycin is a complex comprised of three components, neomycin A, B, and C. Neomycin B, also known as [framycetin], is the most active component of the complex and neomycin C is the isomer o... | Major | 2 | [
[
[
1481,
25,
361
]
],
[
[
1481,
25,
1132
],
[
1132,
24,
361
]
],
[
[
1481,
24,
242
],
[
242,
63,
361
]
],
[
[
1481,
25,
1448
],
[
1448,
... | [
[
[
"Polymyxin B",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Neomycin"
]
],
[
[
"Polymyxin B",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Gentamicin"
],
[
"Gentamicin",
"{u} m... | Polymyxin B may lead to a major life threatening interaction when taken with Gentamicin and Gentamicin may cause a moderate interaction that could exacerbate diseases when taken with Neomycin
Polymyxin B may cause a moderate interaction that could exacerbate diseases when taken with Remdesivir and Remdesivir may cause ... |
DB00222 | DB01278 | 245 | 1,021 | [
"DDInter825",
"DDInter1506"
] | Glimepiride | Pramlintide | First introduced in 1995, glimepiride is a member of the second-generation sulfonylurea (SU) drug class used for the management of type 2 diabetes mellitus (T2DM) to improve glycemic control. Type 2 diabetes is a metabolic disorder with increasing prevalences worldwide; it is characterized by insulin resistance in acco... | Pramlintide is a relatively new adjunct treatment for diabetes (both type 1 and 2), developed by Amylin Pharmaceuticals. It is derived from amylin, a hormone that is released into the bloodstream, in a similar pattern as insulin, after a meal. Like insulin, amylin is deficient in individuals with diabetes. | Moderate | 1 | [
[
[
245,
24,
1021
]
],
[
[
245,
23,
1103
],
[
1103,
23,
1021
]
],
[
[
245,
63,
1560
],
[
1560,
24,
1021
]
],
[
[
245,
24,
1680
],
[
1680,
... | [
[
[
"Glimepiride",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pramlintide"
]
],
[
[
"Glimepiride",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Amcinonide"
],
[
... | Glimepiride may cause a minor interaction that can limit clinical effects when taken with Amcinonide and Amcinonide may cause a minor interaction that can limit clinical effects when taken with Pramlintide
Glimepiride may cause a moderate interaction that could exacerbate diseases when taken with Pegaspargase and Pegas... |
DB00398 | DB01101 | 79 | 60 | [
"DDInter1702",
"DDInter285"
] | Sorafenib | Capecitabine | Sorafenib is a bi-aryl urea and an oral multikinase inhibitor. It targets cell surface tyrosine kinase receptors and downstream intracellular kinases that are implicated in tumour cell proliferation and tumour angiogenesis. First approved by the FDA and European Commission in 2007 for the treatment of hepatocellular ca... | Capecitabine is an orally-administered chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. Capecitabine is a prodrug, that is enzymatically converted to fluorouracil (antimetabolite) in the tumor, where it inhibits DNA synthesis and slows growth of tumor tissue. | Moderate | 1 | [
[
[
79,
24,
60
]
],
[
[
79,
5,
11570
],
[
11570,
44,
60
]
],
[
[
79,
18,
8569
],
[
8569,
45,
60
]
],
[
[
79,
6,
6017
],
[
6017,
45,
... | [
[
[
"Sorafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Capecitabine"
]
],
[
[
"Sorafenib",
"{u} (Compound) treats {v} (Disease)",
"kidney cancer"
],
[
"kidney cancer",
"{u} (Disease) is trea... | Sorafenib (Compound) treats kidney cancer (Disease) and kidney cancer (Disease) is treated by Capecitabine (Compound)
Sorafenib (Compound) downregulates TYMS (Gene) and TYMS (Gene) is bound by Capecitabine (Compound)
Sorafenib (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Capecitabine (Compound)
Sorafeni... |
DB01193 | DB08865 | 819 | 1,593 | [
"DDInter12",
"DDInter448"
] | Acebutolol | Crizotinib | A cardioselective beta-adrenergic antagonist with little effect on the bronchial receptors. The drug has stabilizing and quinidine-like effects on cardiac rhythm as well as weak inherent sympathomimetic action. | Crizotinib is a tyrosine kinase receptor inhibitor used for the treatment of anaplastic lymphoma kinase (ALK) or ROS1-positive non-small cell lung cancer (NSCLC) tumors, as well as ALK-positive anaplastic large cell lymphoma (ALCL) and inflammatory myofibroblastic tumor (IMT). By targeting the echinoderm microtubule-as... | Moderate | 1 | [
[
[
819,
24,
1593
]
],
[
[
819,
6,
4973
],
[
4973,
45,
1593
]
],
[
[
819,
21,
29093
],
[
29093,
60,
1593
]
],
[
[
819,
23,
286
],
[
286,
... | [
[
[
"Acebutolol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Crizotinib"
]
],
[
[
"Acebutolol",
"{u} (Compound) binds {v} (Gene)",
"ABCB1"
],
[
"ABCB1",
"{u} (Gene) is bound by {v} (Compound)",
... | Acebutolol (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Crizotinib (Compound)
Acebutolol (Compound) causes Fatigue (Side Effect) and Fatigue (Side Effect) is caused by Crizotinib (Compound)
Acebutolol may cause a minor interaction that can limit clinical effects when taken with Magnesium hydroxide and Mag... |
DB00633 | DB01181 | 614 | 1,532 | [
"DDInter520",
"DDInter906"
] | Dexmedetomidine | Ifosfamide | An agonist of receptors, adrenergic alpha-2 that is used in veterinary medicine for its analgesic and sedative properties. It is the racemate of dexmedetomidine. | Ifosfamide is a chemotherapeutic agent chemically related to the nitrogen mustards and a synthetic analog of cyclophosphamide. It is active as an alkylating agent and an immunosuppressive agent. | Moderate | 1 | [
[
[
614,
24,
1532
]
],
[
[
614,
21,
28743
],
[
28743,
60,
1532
]
],
[
[
614,
63,
1648
],
[
1648,
24,
1532
]
],
[
[
614,
24,
401
],
[
401,
... | [
[
[
"Dexmedetomidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ifosfamide"
]
],
[
[
"Dexmedetomidine",
"{u} (Compound) causes {v} (Side Effect)",
"Atrial fibrillation"
],
[
"Atrial fibrillation",
... | Dexmedetomidine (Compound) causes Atrial fibrillation (Side Effect) and Atrial fibrillation (Side Effect) is caused by Ifosfamide (Compound)
Dexmedetomidine may cause a moderate interaction that could exacerbate diseases when taken with Aldesleukin and Aldesleukin may cause a moderate interaction that could exacerbate ... |
DB01141 | DB11730 | 692 | 351 | [
"DDInter1208",
"DDInter1588"
] | Micafungin | Ribociclib | Micafungin is an antifungal drug. It belongs to the antifungal class of compounds known as echinocandins and exerts its effect by inhibiting the synthesis of 1,3-beta-D-glucan, an integral component of the fungal cell wall. | Ribociclib is a selective cyclin-dependent kinase inhibitor, a class of drugs that help slow the progression of cancer by inhibiting two proteins called cyclin-dependent kinase 4 and 6 (CDK4/6). These proteins, when over-activated, can enable cancer cells to grow and divide too quickly. Targeting CDK4/6 with enhanced p... | Moderate | 1 | [
[
[
692,
24,
351
]
],
[
[
692,
63,
629
],
[
629,
24,
351
]
],
[
[
692,
63,
629
],
[
629,
24,
222
],
[
222,
23,
351
]
],
[
[
692,
1,
... | [
[
[
"Micafungin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ribociclib"
]
],
[
[
"Micafungin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sirolimus"
],
[
... | Micafungin may cause a moderate interaction that could exacerbate diseases when taken with Sirolimus and Sirolimus may cause a moderate interaction that could exacerbate diseases when taken with Ribociclib
Micafungin may cause a moderate interaction that could exacerbate diseases when taken with Sirolimus and Sirolimus... |
DB00414 | DB06203 | 590 | 1,002 | [
"DDInter16",
"DDInter51"
] | Acetohexamide | Alogliptin | A sulfonylurea hypoglycemic agent that is metabolized in the liver to 1-hydrohexamide. Acetohexamide has been discontinued in the US market. | Alogliptin is a selective, orally-bioavailable inhibitor of enzymatic activity of dipeptidyl peptidase-4 (DPP-4). Chemically, alogliptin is prepared as a benzoate salt and exists predominantly as the R-enantiomer (>99%). It undergoes little or no chiral conversion in vivo to the (S)-enantiomer. FDA approved January 25,... | Moderate | 1 | [
[
[
590,
24,
1002
]
],
[
[
590,
24,
1281
],
[
1281,
40,
1002
]
],
[
[
590,
62,
1103
],
[
1103,
23,
1002
]
],
[
[
590,
24,
504
],
[
504,
... | [
[
[
"Acetohexamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alogliptin"
]
],
[
[
"Acetohexamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Linagliptin"
],
... | Acetohexamide may cause a moderate interaction that could exacerbate diseases when taken with Linagliptin and Linagliptin (Compound) resembles Alogliptin (Compound)
Acetohexamide may cause a minor interaction that can limit clinical effects when taken with Amcinonide and Amcinonide may cause a minor interaction that ca... |
DB00408 | DB01246 | 1,408 | 820 | [
"DDInter1099",
"DDInter45"
] | Loxapine | Alimemazine | An antipsychotic agent used in schizophrenia. [PubChem] | A phenothiazine derivative that is used as an antipruritic. | Moderate | 1 | [
[
[
1408,
24,
820
]
],
[
[
1408,
24,
104
],
[
104,
40,
820
]
],
[
[
1408,
24,
401
],
[
401,
24,
820
]
],
[
[
1408,
24,
649
],
[
649,
... | [
[
[
"Loxapine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alimemazine"
]
],
[
[
"Loxapine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methdilazine"
],
[
... | Loxapine may cause a moderate interaction that could exacerbate diseases when taken with Methdilazine and Methdilazine (Compound) resembles Alimemazine (Compound)
Loxapine may cause a moderate interaction that could exacerbate diseases when taken with Promethazine and Promethazine may cause a moderate interaction that ... |
DB00843 | DB12130 | 479 | 1,017 | [
"DDInter583",
"DDInter1094"
] | Donepezil | Lorlatinib | In 2016, the global burden of dementia was estimated to be 43.8 million, demonstrating a significant increase from a global prevalence of 20.2 million in 1990. Donepezil, also known as Aricept, is a piperidine derivative acetylcholinesterase inhibitor used in the management of the dementia of Alzheimer's Disease, and i... | Lorlatinib is a third-generation ALK tyrosine kinase inhibitor (TKI) for patients with ALK-positive metastatic non-small cell lung cancer which was first approved by the US FDA in November of 2018. It was subsequently approved by the EMA in 2019 for the treatment of select patients with previously treated advanced ALK-... | Moderate | 1 | [
[
[
479,
24,
1017
]
],
[
[
479,
63,
1101
],
[
1101,
23,
1017
]
],
[
[
479,
24,
976
],
[
976,
24,
1017
]
],
[
[
479,
63,
888
],
[
888,
... | [
[
[
"Donepezil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lorlatinib"
]
],
[
[
"Donepezil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bexarotene"
],
[
... | Donepezil may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexarotene may cause a minor interaction that can limit clinical effects when taken with Lorlatinib
Donepezil may cause a moderate interaction that could exacerbate diseases when taken with Tofacitinib and Tofacitin... |
DB00196 | DB01069 | 600 | 401 | [
"DDInter743",
"DDInter1533"
] | Fluconazole | Promethazine | Fluconazole, commonly known as _Diflucan_, is an antifungal drug used for the treatment of both systemic and superficial fungal infections in a variety of tissues. It was initially approved by the FDA in 1990. This drug is an _azole_ antifungal, in the same drug family as [ketoconazole] and [itraconazole]. Fluconazole ... | Promethazine, originally known as 3,277 R.P., is an N-dimethylaminopropyl derivative of [phenothiazine] that was developed in France in 1946. Promethazine antagonizes a variety of receptors, allowing it to be used for a number of indications including allergic reactions, pain, sedation, nausea, and vomiting.[A189907,A1... | Moderate | 1 | [
[
[
600,
24,
401
]
],
[
[
600,
24,
1264
],
[
1264,
63,
401
]
],
[
[
600,
24,
1236
],
[
1236,
24,
401
]
],
[
[
600,
6,
6017
],
[
6017,
... | [
[
[
"Fluconazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Promethazine"
]
],
[
[
"Fluconazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxepin"
],
[
... | Fluconazole may cause a moderate interaction that could exacerbate diseases when taken with Doxepin and Doxepin may cause a moderate interaction that could exacerbate diseases when taken with Promethazine
Fluconazole may cause a moderate interaction that could exacerbate diseases when taken with Carbamazepine and Carba... |
DB08904 | DB11730 | 375 | 351 | [
"DDInter342",
"DDInter1588"
] | Certolizumab pegol | Ribociclib | Certolizumab pegol is a pegylated monoclonal antibody against the tumor necrosis factor-alpha (TNF-alpha). It is formed with a humanized Fab fragment of 50 kDa, from an IgG 1 isotype, fused to a 40 kDa polyethylene glycol moiety replacing the Fc antibody region. The absence of the Fc region was ideated to prevent compl... | Ribociclib is a selective cyclin-dependent kinase inhibitor, a class of drugs that help slow the progression of cancer by inhibiting two proteins called cyclin-dependent kinase 4 and 6 (CDK4/6). These proteins, when over-activated, can enable cancer cells to grow and divide too quickly. Targeting CDK4/6 with enhanced p... | Major | 2 | [
[
[
375,
25,
351
]
],
[
[
375,
63,
112
],
[
112,
23,
351
]
],
[
[
375,
64,
310
],
[
310,
24,
351
]
],
[
[
375,
63,
597
],
[
597,
24,... | [
[
[
"Certolizumab pegol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ribociclib"
]
],
[
[
"Certolizumab pegol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metronidazole"
],
... | Certolizumab pegol may cause a moderate interaction that could exacerbate diseases when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Ribociclib
Certolizumab pegol may lead to a major life threatening interaction when taken with Cabazitaxel and ... |
DB00712 | DB00827 | 1,274 | 646 | [
"DDInter763",
"DDInter383"
] | Flurbiprofen | Cinoxacin | Flurbiprofen, a propionic acid derivative, is a nonsteroidal anti-inflammatory agent (NSAIA) with antipyretic and analgesic activity. Oral formulations of flurbiprofen may be used for the symptomatic treatment of rheumatoid arthritis, osteoarthritis and anklylosing spondylitis. Flurbiprofen may also be used topically p... | Synthetic antimicrobial related to oxolinic acid and nalidixic acid and used in urinary tract infections. | Moderate | 1 | [
[
[
1274,
24,
646
]
],
[
[
1274,
6,
10612
],
[
10612,
45,
646
]
],
[
[
1274,
21,
28691
],
[
28691,
60,
646
]
],
[
[
1274,
63,
372
],
[
372... | [
[
[
"Flurbiprofen",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cinoxacin"
]
],
[
[
"Flurbiprofen",
"{u} (Compound) binds {v} (Gene)",
"SLC22A6"
],
[
"SLC22A6",
"{u} (Gene) is bound by {v} (Compou... | Flurbiprofen (Compound) binds SLC22A6 (Gene) and SLC22A6 (Gene) is bound by Cinoxacin (Compound)
Flurbiprofen (Compound) causes Somnolence (Side Effect) and Somnolence (Side Effect) is caused by Cinoxacin (Compound)
Flurbiprofen may cause a moderate interaction that could exacerbate diseases when taken with Clofarabine... |
DB00060 | DB00584 | 912 | 610 | [
"DDInter947",
"DDInter638"
] | Interferon beta-1a | Enalapril | Human interferon beta (166 residues), glycosylated, MW=22.5kD. It is produced by mammalian cells (Chinese Hamster Ovary cells) into which the human interferon beta gene has been introduced. The amino acid sequence is identical to that of natural human interferon beta. | Enalapril is a prodrug belonging to the angiotensin-converting enzyme (ACE) inhibitor drug class that works on the renin-angiotensin-aldosterone system, which is responsible for the regulation of blood pressure and fluid and electrolyte homeostasis. Enalapril is an orally-active and long-acting nonsulphydryl antihypert... | Moderate | 1 | [
[
[
912,
24,
610
]
],
[
[
912,
24,
743
],
[
743,
1,
610
]
],
[
[
912,
24,
954
],
[
954,
40,
610
]
],
[
[
912,
63,
1648
],
[
1648,
24... | [
[
[
"Interferon beta-1a",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enalapril"
]
],
[
[
"Interferon beta-1a",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lisinopril"
... | Interferon beta-1a may cause a moderate interaction that could exacerbate diseases when taken with Lisinopril and Lisinopril (Compound) resembles Enalapril (Compound)
Interferon beta-1a may cause a moderate interaction that could exacerbate diseases when taken with Quinapril and Quinapril (Compound) resembles Enalapril... |
DB01067 | DB03754 | 959 | 1,400 | [
"DDInter826",
"DDInter1883"
] | Glipizide | Tromethamine | Glipizide is an oral hypoglycemic agent in the second-generation sulfonylurea drug class that is used to control blood sugar levels in patients with type 2 diabetes mellitus. It was first introduced in 1984 and is available in various countries including Canada and the U.S. According to the 2018 Clinical Practice Guide... | An organic amine proton acceptor. It is used in the synthesis of surface-active agents and pharmaceuticals; as an emulsifying agent for cosmetic creams and lotions, mineral oil and paraffin wax emulsions, as a biological buffer, and used as an alkalizer. (From Merck, 11th ed; Martindale, The Extra Pharmacopoeia, 30th e... | Minor | 0 | [
[
[
959,
23,
1400
]
],
[
[
959,
40,
1411
],
[
1411,
23,
1400
]
],
[
[
959,
24,
1529
],
[
1529,
24,
1400
]
],
[
[
959,
63,
1445
],
[
1445,
... | [
[
[
"Glipizide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Tromethamine"
]
],
[
[
"Glipizide",
"{u} (Compound) resembles {v} (Compound)",
"Tolbutamide"
],
[
"Tolbutamide",
"{u} may cause a minor i... | Glipizide (Compound) resembles Tolbutamide (Compound) and Tolbutamide may cause a minor interaction that can limit clinical effects when taken with Tromethamine
Glipizide may cause a moderate interaction that could exacerbate diseases when taken with Metamfetamine and Metamfetamine may cause a moderate interaction that... |
DB00013 | DB01050 | 1,255 | 848 | [
"DDInter1905",
"DDInter900"
] | Urokinase | Ibuprofen | Urokinase is an endogenous peptide that is cleaved in the presence of plasmin between lysine 158 and isoleucine 159 to yield active urokinase. Urokinase remains connected between these 2 chains by a sulfhydryl bond. Urokinase was granted FDA approval on 16 January 1978. | Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics. The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin. Ibuprofen was finally p... | Moderate | 1 | [
[
[
1255,
24,
848
]
],
[
[
1255,
23,
297
],
[
297,
62,
848
]
],
[
[
1255,
24,
831
],
[
831,
24,
848
]
],
[
[
1255,
64,
1578
],
[
1578,
... | [
[
[
"Urokinase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ibuprofen"
]
],
[
[
"Urokinase",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Clove"
],
[
"Clove... | Urokinase may cause a minor interaction that can limit clinical effects when taken with Clove and Clove may cause a minor interaction that can limit clinical effects when taken with Ibuprofen
Urokinase may cause a moderate interaction that could exacerbate diseases when taken with Indomethacin and Indomethacin may caus... |
DB00069 | DB08871 | 367 | 36 | [
"DDInter946",
"DDInter666"
] | Interferon alfacon-1 | Eribulin | Interferon alfacon-1 is a recombinant non-naturally occurring type-I interferon. The 166-amino acid sequence of Interferon alfacon-1 was derived by scanning the sequences of several natural interferon alpha subtypes and assigning the most frequently observed amino acid in each corresponding position. Four additional am... | Eribulin is a microtubule inhibitor indicated for the treatment of patients with metastatic breast cancer who have previously received at least two chemotherapeutic regimens for the treatment of metastatic disease. Eribulin was isolated from the marine sponge Halichondria okadai. Eribulin is also being investigated for... | Moderate | 1 | [
[
[
367,
24,
36
]
],
[
[
367,
24,
563
],
[
563,
24,
36
]
],
[
[
367,
24,
713
],
[
713,
63,
36
]
],
[
[
367,
63,
268
],
[
268,
24,
... | [
[
[
"Interferon alfacon-1",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Eribulin"
]
],
[
[
"Interferon alfacon-1",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ganciclov... | Interferon alfacon-1 may cause a moderate interaction that could exacerbate diseases when taken with Ganciclovir and Ganciclovir may cause a moderate interaction that could exacerbate diseases when taken with Eribulin
Interferon alfacon-1 may cause a moderate interaction that could exacerbate diseases when taken with D... |
DB00029 | DB08875 | 25 | 1,618 | [
"DDInter99",
"DDInter262"
] | Anistreplase | Cabozantinib | Human tissue plasminogen activator, purified, glycosylated, 527 residues purified from CHO cells. Eminase is a lyophilized (freeze-dried) formulation of anistreplase, the p-anisoyl derivative of the primary Lys-plasminogen-streptokinase activator complex (a complex of Lys-plasminogen and streptokinase). A p-anisoyl gro... | Cabozantinib was first approved in 2012 and is a non-specific tyrosine kinase inhibitor. It was initially approved in the US under the brand name Cometriq, which is indicated for the treatment of metastatic medullary thyroid cancer. In 2016, a capsule formulation (Cabometyx) was approved for the treatment of advanced r... | Major | 2 | [
[
[
25,
25,
1618
]
],
[
[
25,
24,
41
],
[
41,
63,
1618
]
],
[
[
25,
24,
222
],
[
222,
24,
1618
]
],
[
[
25,
24,
885
],
[
885,
25,
... | [
[
[
"Anistreplase",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cabozantinib"
]
],
[
[
"Anistreplase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levomilnacipran"
],
[
... | Anistreplase may cause a moderate interaction that could exacerbate diseases when taken with Levomilnacipran and Levomilnacipran may cause a moderate interaction that could exacerbate diseases when taken with Cabozantinib
Anistreplase may cause a moderate interaction that could exacerbate diseases when taken with Sibut... |
DB00065 | DB06605 | 581 | 1,409 | [
"DDInter923",
"DDInter108"
] | Infliximab | Apixaban | Infliximab is a tumor necrosis factor (TNF-alpha or TNF-α) blocker and a chimeric monoclonal IgG1 antibody composed of human constant (75%) and murine variable (25%) regions. Infliximab is produced by a recombinant cell line cultured by continuous perfusion. Tumor necrosis factor-alpha (TNF-α) is a key proinflammatory ... | Apixaban is an oral, direct, and highly selective factor Xa (FXa) inhibitor of both free and bound FXa, as well as prothrombinase, independent of antithrombin III for the prevention and treatment of thromboembolic diseases[Label,A6897]. It is marketed under the name Eliquis[Label,L6043]. Apixaban was approved by the FD... | Moderate | 1 | [
[
[
581,
24,
1409
]
],
[
[
581,
24,
1593
],
[
1593,
63,
1409
]
],
[
[
581,
25,
990
],
[
990,
63,
1409
]
],
[
[
581,
24,
655
],
[
655,
... | [
[
[
"Infliximab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Apixaban"
]
],
[
[
"Infliximab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Crizotinib"
],
[
... | Infliximab may cause a moderate interaction that could exacerbate diseases when taken with Crizotinib and Crizotinib may cause a moderate interaction that could exacerbate diseases when taken with Apixaban
Infliximab may lead to a major life threatening interaction when taken with Lomitapide and Lomitapide may cause a ... |
DB00736 | DB09061 | 660 | 1,627 | [
"DDInter676",
"DDInter284"
] | Esomeprazole | Cannabidiol | Esomeprazole, sold under the brand name Nexium, is a proton pump inhibitor (PPI) medication used for the management of gastroesophageal reflux disease (GERD), for gastric protection to prevent recurrence of stomach ulcers or gastric damage from chronic use of NSAIDs, and for the treatment of pathological hypersecretory... | Cannabidiol, or CBD, is one of at least 85 active cannabinoids identified within the Cannabis plant. It is a major phytocannabinoid, accounting for up to 40% of the Cannabis plant's extract, that binds to a wide variety of physiological targets of the endocannabinoid system within the body. Although the exact medical i... | Minor | 0 | [
[
[
660,
23,
1627
]
],
[
[
660,
23,
609
],
[
609,
23,
1627
]
],
[
[
660,
63,
600
],
[
600,
23,
1627
]
],
[
[
660,
1,
1215
],
[
1215,
... | [
[
[
"Esomeprazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Cannabidiol"
]
],
[
[
"Esomeprazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Clarithromycin"
],
... | Esomeprazole may cause a minor interaction that can limit clinical effects when taken with Clarithromycin and Clarithromycin may cause a minor interaction that can limit clinical effects when taken with Cannabidiol
Esomeprazole may cause a moderate interaction that could exacerbate diseases when taken with Fluconazole ... |
DB00227 | DB12010 | 1,463 | 214 | [
"DDInter1098",
"DDInter785"
] | Lovastatin | Fostamatinib | Lovastatin, also known as the brand name product Mevacor, is a lipid-lowering drug and fungal metabolite derived synthetically from a fermentation product of _Aspergillus terreus_. Originally named Mevinolin, lovastatin belongs to the statin class of medications, which are used to lower the risk of cardiovascular disea... | Fostamatinib has been investigated for the treatment and basic science of Rheumatoid Arthritis and Immune Thrombocytopenic Purpura (ITP). It was approved on April 17, 2018, under the trade name Tavalisse for use in ITP [L2644, FDA Label]. Fostamatinib has also been granted orphan drug status by the FDA . Recently, fost... | Moderate | 1 | [
[
[
1463,
24,
214
]
],
[
[
1463,
24,
723
],
[
723,
24,
214
]
],
[
[
1463,
64,
600
],
[
600,
24,
214
]
],
[
[
1463,
63,
1324
],
[
1324,
... | [
[
[
"Lovastatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fostamatinib"
]
],
[
[
"Lovastatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aprepitant"
],
[
... | Lovastatin may cause a moderate interaction that could exacerbate diseases when taken with Aprepitant and Aprepitant may cause a moderate interaction that could exacerbate diseases when taken with Fostamatinib
Lovastatin may lead to a major life threatening interaction when taken with Fluconazole and Fluconazole may ca... |
DB01240 | DB03404 | 885 | 765 | [
"DDInter657",
"DDInter855"
] | Epoprostenol | Hemin | A prostaglandin that is a powerful vasodilator and inhibits platelet aggregation. It is biosynthesized enzymatically from prostaglandin endoperoxides in human vascular tissue. The sodium salt has been also used to treat primary pulmonary hypertension. | Hemin (trade name Panhematin) is an iron-containing porphyrin. More specifically, it is protoporphyrin IX containing a ferric iron ion (heme B) with a chloride ligand. | Moderate | 1 | [
[
[
885,
24,
765
]
],
[
[
885,
24,
840
],
[
840,
63,
765
]
],
[
[
885,
63,
291
],
[
291,
24,
765
]
],
[
[
885,
64,
1172
],
[
1172,
2... | [
[
[
"Epoprostenol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hemin"
]
],
[
[
"Epoprostenol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vorapaxar"
],
[
... | Epoprostenol may cause a moderate interaction that could exacerbate diseases when taken with Vorapaxar and Vorapaxar may cause a moderate interaction that could exacerbate diseases when taken with Hemin
Epoprostenol may cause a moderate interaction that could exacerbate diseases when taken with Argatroban and Argatroba... |
DB06616 | DB11837 | 594 | 1,297 | [
"DDInter224",
"DDInter1351"
] | Bosutinib | Osilodrostat | Bosutinib is a 7-alkoxy-3-quinolinecarbonitrile that functions as a potent, dual SRC and ABL tyrosine kinase inhibitor indicated for chronic myelogenous leukemia (CML), specifically Philadelphia chromosome-positive (Ph+) CML. Philadelphia chromosome is a hallmark of CML due to the reciprocal translocation t(9;22)(q34;q... | Osilodrostat is an inhibitor of 11β-hydroxylase (also referred to as CYP11B1), the enzyme that catalyzes the final step in the biosynthesis of endogenous cortisol. It is used to lower circulating cortisol levels in the treatment of Cushing's disease, a disorder in which cortisol levels are chronically and supraphysiolo... | Moderate | 1 | [
[
[
594,
24,
1297
]
],
[
[
594,
62,
112
],
[
112,
23,
1297
]
],
[
[
594,
24,
1320
],
[
1320,
63,
1297
]
],
[
[
594,
63,
623
],
[
623,
... | [
[
[
"Bosutinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Osilodrostat"
]
],
[
[
"Bosutinib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
... | Bosutinib may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Osilodrostat
Bosutinib may cause a moderate interaction that could exacerbate diseases when taken with Elagolix and Elagol... |
DB00848 | DB14409 | 281 | 1,129 | [
"DDInter1044",
"DDInter867"
] | Levamisole | Human adenovirus e serotype 4 strain cl-68578 antigen | Levamisole is an antihelminthic drug that was commonly used for the treatment of parasitic, viral, and bacterial infections. It was manufactured by _Janssen_ and first used in 1969 as an agent to treat worm infestations Levamisole was approved by the FDA in 1990 as an adjuvant treatment for colon cancer. Prior to this,... | Human adenovirus e serotype 4 strain cl-68578 antigen is a vaccine. | Moderate | 1 | [
[
[
281,
24,
1129
]
],
[
[
281,
64,
1057
],
[
1057,
24,
1129
]
],
[
[
281,
24,
1683
],
[
1683,
24,
1129
]
],
[
[
281,
63,
1184
],
[
1184,
... | [
[
[
"Levamisole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Human adenovirus e serotype 4 strain cl-68578 antigen"
]
],
[
[
"Levamisole",
"{u} may lead to a major life threatening interaction when taken with {v}",
... | Levamisole may lead to a major life threatening interaction when taken with Etanercept and Etanercept may cause a moderate interaction that could exacerbate diseases when taken with Human adenovirus e serotype 4 strain cl-68578 antigen
Levamisole may cause a moderate interaction that could exacerbate diseases when take... |
DB00055 | DB04932 | 834 | 1,564 | [
"DDInter605",
"DDInter491"
] | Drotrecogin alfa | Defibrotide | Drotrecogin alfa is activated human protein C that is synthesized by recombinant DNA technology. It is a glycoprotein of approximately 55 kilodalton molecular weight, consisting of a heavy chain and a light chain linked by a disulfide bond. Drotrecogin alfa was withdrawn from the market after a major study indicated th... | Defibrotide is the sodium salt of a mixture of single-stranded oligodeoxyribonucleotides derived from porcine mucosal DNA. It has been shown to have antithrombotic, anti-inflammatory and anti-ischemic properties (but without associated significant systemic anticoagulant effects). It is marketed under the brand names Da... | Major | 2 | [
[
[
834,
25,
1564
]
],
[
[
834,
23,
539
],
[
539,
62,
1564
]
],
[
[
834,
25,
914
],
[
914,
24,
1564
]
],
[
[
834,
24,
1039
],
[
1039,
... | [
[
[
"Drotrecogin alfa",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Defibrotide"
]
],
[
[
"Drotrecogin alfa",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Capsicum"
],
[
"C... | Drotrecogin alfa may cause a minor interaction that can limit clinical effects when taken with Capsicum and Capsicum may cause a minor interaction that can limit clinical effects when taken with Defibrotide
Drotrecogin alfa may lead to a major life threatening interaction when taken with Diflunisal and Diflunisal may c... |
DB00963 | DB01166 | 1,263 | 477 | [
"DDInter241",
"DDInter379"
] | Bromfenac | Cilostazol | Bromfenac is a nonsteroidal anti-inflammatory drug (NSAID) for ophthalmic use. Ophthalmic NSAIDs are becoming a cornerstone for the management of ocular pain and inflammation. Their well-characterized anti-inflammatory activity, analgesic property, and established safety record have also made NSAIDs an important tool f... | Cilostazol is a quinolinone derivative and antiplatelet agent with vasodilating properties that has been used in the symptomatic treatment of intermittent claudication in patients with peripheral ischaemia. It is marketed under the brand name Pletal by Otsuka Pharmaceutical Co.. Cilostazol works by inhibiting both prim... | Moderate | 1 | [
[
[
1263,
24,
477
]
],
[
[
1263,
7,
4450
],
[
4450,
46,
477
]
],
[
[
1263,
18,
2201
],
[
2201,
57,
477
]
],
[
[
1263,
21,
28688
],
[
28688... | [
[
[
"Bromfenac",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cilostazol"
]
],
[
[
"Bromfenac",
"{u} (Compound) upregulates {v} (Gene)",
"RRP8"
],
[
"RRP8",
"{u} (Gene) is upregulated by {v} (Compo... | Bromfenac (Compound) upregulates RRP8 (Gene) and RRP8 (Gene) is upregulated by Cilostazol (Compound)
Bromfenac (Compound) downregulates PPP2R5E (Gene) and PPP2R5E (Gene) is downregulated by Cilostazol (Compound)
Bromfenac (Compound) causes Epistaxis (Side Effect) and Epistaxis (Side Effect) is caused by Cilostazol (Com... |
DB00008 | DB00563 | 491 | 663 | [
"DDInter1407",
"DDInter1174"
] | Peginterferon alfa-2a | Methotrexate | Peginterferon alfa-2a is a form of recombinant interferon used as part of combination therapy to treat chronic Hepatitis C, an infectious liver disease caused by infection with Hepatitis C Virus (HCV). HCV is a single-stranded RNA virus that is categorized into nine distinct genotypes, with genotype 1 being the most co... | Methotrexate is a folate derivative that inhibits several enzymes responsible for nucleotide synthesis. This inhibition leads to suppression of inflammation as well as prevention of cell division. Because of these effects, methotrexate is often used to treat inflammation caused by arthritis or to control cell division ... | Moderate | 1 | [
[
[
491,
24,
663
]
],
[
[
491,
24,
126
],
[
126,
62,
663
]
],
[
[
491,
24,
738
],
[
738,
63,
663
]
],
[
[
491,
25,
876
],
[
876,
63,... | [
[
[
"Peginterferon alfa-2a",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methotrexate"
]
],
[
[
"Peginterferon alfa-2a",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"War... | Peginterferon alfa-2a may cause a moderate interaction that could exacerbate diseases when taken with Warfarin and Warfarin may cause a minor interaction that can limit clinical effects when taken with Methotrexate
Peginterferon alfa-2a may cause a moderate interaction that could exacerbate diseases when taken with Nir... |
DB00305 | DB09074 | 377 | 1,362 | [
"DDInter1232",
"DDInter1327"
] | Mitomycin | Olaparib | Mitomycin is an antineoplastic antibiotic first isolated by Japanese microbiologists in the 1950s from cultures of _Streptomyces caespitosus_.[L12867,A193419] It is an alkylating agent that inhibits DNA synthesis (and, at higher concentrations, RNA and protein synthesis) by cross-linking the complementary strands of th... | Olaparib is a selective and potent inhibitor of poly (ADP-ribose) polymerase (PARP) enzymes, PARP1 and PARP2.[L41100, L40908, L43792] PARP inhibitors represent a novel class of anti-cancer therapy and they work by taking advantage of a defect in DNA repair in cancer cells with BRCA mutations and inducing cell death. Ol... | Moderate | 1 | [
[
[
377,
24,
1362
]
],
[
[
377,
24,
896
],
[
896,
24,
1362
]
],
[
[
377,
63,
552
],
[
552,
24,
1362
]
],
[
[
377,
24,
385
],
[
385,
... | [
[
[
"Mitomycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Olaparib"
]
],
[
[
"Mitomycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Etoposide"
],
[
"... | Mitomycin may cause a moderate interaction that could exacerbate diseases when taken with Etoposide and Etoposide may cause a moderate interaction that could exacerbate diseases when taken with Olaparib
Mitomycin may cause a moderate interaction that could exacerbate diseases when taken with Carmustine and Carmustine m... |
DB06788 | DB08865 | 1,616 | 1,593 | [
"DDInter864",
"DDInter448"
] | Histrelin | Crizotinib | Histrelin is a gonadotropin-releasing hormone (GnRH) agonist that acts as a potent inhibitor of gonadotropin when administered as an implant delivering continuous therapeutic doses. This drug is a synthetic analog of naturally occurring GnRH with a higher potency. Histrelin implants are non-biodegradable, diffusion-con... | Crizotinib is a tyrosine kinase receptor inhibitor used for the treatment of anaplastic lymphoma kinase (ALK) or ROS1-positive non-small cell lung cancer (NSCLC) tumors, as well as ALK-positive anaplastic large cell lymphoma (ALCL) and inflammatory myofibroblastic tumor (IMT). By targeting the echinoderm microtubule-as... | Major | 2 | [
[
[
1616,
25,
1593
]
],
[
[
1616,
63,
479
],
[
479,
23,
1593
]
],
[
[
1616,
62,
1247
],
[
1247,
23,
1593
]
],
[
[
1616,
24,
286
],
[
286,
... | [
[
[
"Histrelin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Crizotinib"
]
],
[
[
"Histrelin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Donepezil"
],
[
"Donepezil",
... | Histrelin may cause a moderate interaction that could exacerbate diseases when taken with Donepezil and Donepezil may cause a minor interaction that can limit clinical effects when taken with Crizotinib
Histrelin may cause a minor interaction that can limit clinical effects when taken with Sulfamethoxazole and Sulfamet... |
DB00285 | DB00574 | 1,100 | 121 | [
"DDInter1927",
"DDInter717"
] | Venlafaxine | Fenfluramine | Venlafaxine is an antidepressant and a serotonin and norepinephrine reuptake inhibitor (SNRI). Its active metabolite, [desvenlafaxine], works by blocking the reuptake of serotonin and norepinephrine, which are key neurotransmitters in mood regulation. Venlafaxine is officially approved to treat major depressive disorde... | Dravet syndrome is a pediatric encephalopathy that typically manifests within the first year of life following exposure to elevated temperatures. It is characterized by recurrent pharmacoresistant seizures, which increase in frequency and severity with disease progression. Concomitantly with these seizures, patients ty... | Major | 2 | [
[
[
1100,
25,
121
]
],
[
[
1100,
63,
366
],
[
366,
24,
121
]
],
[
[
1100,
24,
292
],
[
292,
63,
121
]
],
[
[
1100,
25,
868
],
[
868,
... | [
[
[
"Venlafaxine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fenfluramine"
]
],
[
[
"Venlafaxine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Eptifibatide"
],
[
"Epti... | Venlafaxine may cause a moderate interaction that could exacerbate diseases when taken with Eptifibatide and Eptifibatide may cause a moderate interaction that could exacerbate diseases when taken with Fenfluramine
Venlafaxine may cause a moderate interaction that could exacerbate diseases when taken with Regorafenib a... |
DB00307 | DB00553 | 1,101 | 92 | [
"DDInter202",
"DDInter1177"
] | Bexarotene | Methoxsalen | Bexarotene (Targretin) is an antineoplastic agent indicated by the FDA for Cutaneous T cell lymphoma. It has been used off-label for lung cancer, breast cancer, and Kaposi's sarcoma. | A naturally occurring furocoumarin compound found in several species of plants, including Psoralea corylifolia. It is a photoactive substance that forms DNA adducts in the presence of ultraviolet A irradiation. | Moderate | 1 | [
[
[
1101,
24,
92
]
],
[
[
1101,
5,
11555
],
[
11555,
44,
92
]
],
[
[
1101,
6,
8374
],
[
8374,
45,
92
]
],
[
[
1101,
21,
28680
],
[
28680,
... | [
[
[
"Bexarotene",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methoxsalen"
]
],
[
[
"Bexarotene",
"{u} (Compound) treats {v} (Disease)",
"hematologic cancer"
],
[
"hematologic cancer",
"{u} (Disea... | Bexarotene (Compound) treats hematologic cancer (Disease) and hematologic cancer (Disease) is treated by Methoxsalen (Compound)
Bexarotene (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Methoxsalen (Compound)
Bexarotene (Compound) causes Rash (Side Effect) and Rash (Side Effect) is caused by Methoxsalen (... |
DB00418 | DB06595 | 536 | 1,491 | [
"DDInter1650",
"DDInter1214"
] | Secobarbital | Midostaurin | Secobarbital (marketed by Eli Lilly and Company under the brand names Seconal and Tuinal) is a barbiturate derivative drug with anaesthetic, anticonvulsant, sedative and hypnotic properties. It is commonly known as quinalbarbitone in the United Kingdom. | Midostaurin (as Rydapt) is a multitarget kinase inhibitor for the treatment for adult patients with newly diagnosed acute myeloid leukemia (AML) who have a specific genetic mutation called FLT3. It was initially characterized as a potential broad-spectrum antineoplastic agent, with activity toward diverse solid and hem... | Moderate | 1 | [
[
[
536,
24,
1491
]
],
[
[
536,
24,
1135
],
[
1135,
62,
1491
]
],
[
[
536,
24,
112
],
[
112,
23,
1491
]
],
[
[
536,
24,
761
],
[
761,
... | [
[
[
"Secobarbital",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Midostaurin"
]
],
[
[
"Secobarbital",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Naloxegol"
],
... | Secobarbital may cause a moderate interaction that could exacerbate diseases when taken with Naloxegol and Naloxegol may cause a minor interaction that can limit clinical effects when taken with Midostaurin
Secobarbital may cause a moderate interaction that could exacerbate diseases when taken with Metronidazole and Me... |
DB05773 | DB08860 | 1,047 | 788 | [
"DDInter1848",
"DDInter1479"
] | Trastuzumab emtansine | Pitavastatin | Trastuzumab emtansine, formerly called Trastuzumab-DM1 (T-DM1) is a first-in-class HER2 antibody drug conjugate (ADC) comprised of Genentech's trastuzumab antibody linked to ImmunoGen's cell-killing agent, DM1. T-DM1 combines two strategies-- anti-HER2 activity and targeted intracellular delivery of the potent anti-mic... | Pitavastatin, also known as the brand name product Livalo, is a lipid-lowering drug belonging to the statin class of medications. By inhibiting the endogenous production of cholesterol within the liver, statins lower abnormal cholesterol and lipid levels and ultimately reduce the risk of cardiovascular disease. More sp... | Moderate | 1 | [
[
[
1047,
24,
788
]
],
[
[
1047,
63,
671
],
[
671,
1,
788
]
],
[
[
1047,
63,
700
],
[
700,
40,
788
]
],
[
[
1047,
64,
126
],
[
126,
... | [
[
[
"Trastuzumab emtansine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pitavastatin"
]
],
[
[
"Trastuzumab emtansine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Flu... | Trastuzumab emtansine may cause a moderate interaction that could exacerbate diseases when taken with Fluvastatin and Fluvastatin (Compound) resembles Pitavastatin (Compound)
Trastuzumab emtansine may cause a moderate interaction that could exacerbate diseases when taken with Atorvastatin and Atorvastatin (Compound) re... |
DB01211 | DB13007 | 609 | 1,060 | [
"DDInter393",
"DDInter642"
] | Clarithromycin | Enfortumab vedotin | Clarithromycin, a semisynthetic macrolide antibiotic derived from erythromycin, inhibits bacterial protein synthesis by binding to the bacterial 50S ribosomal subunit. Binding inhibits peptidyl transferase activity and interferes with amino acid translocation during the translation and protein assembly process. Clarith... | Enfortumab vedotin is an antibody-drug conjugate used in the treatment of patients with advanced, treatment-resistant urothelial cancers. It is comprised of a fully human monoclonal antibody targeted against Nectin-4 and a microtubule-disrupting chemotherapeutic agent, monomethyl auristatin E (MMAE), joined by a protea... | Major | 2 | [
[
[
609,
25,
1060
]
],
[
[
609,
24,
129
],
[
129,
23,
1060
]
],
[
[
609,
25,
1593
],
[
1593,
24,
1060
]
],
[
[
609,
63,
590
],
[
590,
... | [
[
[
"Clarithromycin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Enfortumab vedotin"
]
],
[
[
"Clarithromycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enzalutamide"
],
[... | Clarithromycin may cause a moderate interaction that could exacerbate diseases when taken with Enzalutamide and Enzalutamide may cause a minor interaction that can limit clinical effects when taken with Enfortumab vedotin
Clarithromycin may lead to a major life threatening interaction when taken with Crizotinib and Cri... |
DB00069 | DB11995 | 367 | 1,634 | [
"DDInter946",
"DDInter143"
] | Interferon alfacon-1 | Avatrombopag | Interferon alfacon-1 is a recombinant non-naturally occurring type-I interferon. The 166-amino acid sequence of Interferon alfacon-1 was derived by scanning the sequences of several natural interferon alpha subtypes and assigning the most frequently observed amino acid in each corresponding position. Four additional am... | Avatrombopag (_Doptelet_), is an orally administered, small molecule thrombopoietin receptor (c-Mpl) agonist that increases platelet number without increasing platelet activation,[A33097,L2824] thereby decreasing the need for blood transfusions. Patients with thrombocytopenia and chronic liver disease often require pla... | Moderate | 1 | [
[
[
367,
24,
1634
]
],
[
[
367,
24,
1613
],
[
1613,
24,
1634
]
],
[
[
367,
63,
912
],
[
912,
24,
1634
]
],
[
[
367,
24,
350
],
[
350,
... | [
[
[
"Interferon alfacon-1",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Avatrombopag"
]
],
[
[
"Interferon alfacon-1",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pegin... | Interferon alfacon-1 may cause a moderate interaction that could exacerbate diseases when taken with Peginterferon beta-1a and Peginterferon beta-1a may cause a moderate interaction that could exacerbate diseases when taken with Avatrombopag
Interferon alfacon-1 may cause a moderate interaction that could exacerbate di... |
DB04861 | DB06791 | 1,592 | 1,446 | [
"DDInter1271",
"DDInter1021"
] | Nebivolol | Lanreotide | Nebivolol is a racemic mixture of 2 enantiomers where one is a beta adrenergic antagonist and the other acts as a cardiac stimulant without beta adrenergic activity. Treatment with nebivolol leads to a greater decrease in systolic and diastolic blood pressure than [atenolol], [propranolol], or [pindolol]. Nebivolol and... | Lanreotide is a drug employed in the management of acromegaly (a hormonal condition caused by excess growth hormone) in addition to symptoms caused by neuroendocrine tumors, especially carcinoid syndrome. This drug is a long-acting analog of the drug somatostatin, a growth hormone inhibitor. Lanreotide is manufactured ... | Moderate | 1 | [
[
[
1592,
24,
1446
]
],
[
[
1592,
24,
549
],
[
549,
24,
1446
]
],
[
[
1592,
63,
1685
],
[
1685,
24,
1446
]
],
[
[
1592,
24,
1344
],
[
1344... | [
[
[
"Nebivolol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lanreotide"
]
],
[
[
"Nebivolol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dapagliflozin"
],
[
... | Nebivolol may cause a moderate interaction that could exacerbate diseases when taken with Dapagliflozin and Dapagliflozin may cause a moderate interaction that could exacerbate diseases when taken with Lanreotide
Nebivolol may cause a moderate interaction that could exacerbate diseases when taken with Insulin human and... |
DB01088 | DB08918 | 714 | 41 | [
"DDInter908",
"DDInter1059"
] | Iloprost | Levomilnacipran | Iloprost is a mimetic of prostacyclin (PGI2; epoprostenol). Iloprost consists of a mixture of the 4R and 4S diastereoisomers at a ratio of approximately 53:47. It is a potent vasodilator with reported anti-thrombotic properties. | Levomilnacipran is a selective serotonin and norepinephrine reuptake inhibitor (SNRI), although it is a more potent inhibitor of norepinephrine reuptake than serotonin reuptake.[A261181, A38560] Levomilnacipran is the more active 1S,2R-enantiomer in the racemate [milnacipran].[A261181, L47956] Once administered, interc... | Moderate | 1 | [
[
[
714,
24,
41
]
],
[
[
714,
24,
901
],
[
901,
40,
41
]
],
[
[
714,
25,
498
],
[
498,
63,
41
]
],
[
[
714,
25,
330
],
[
330,
24,
... | [
[
[
"Iloprost",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levomilnacipran"
]
],
[
[
"Iloprost",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Milnacipran"
],
[
... | Iloprost may cause a moderate interaction that could exacerbate diseases when taken with Milnacipran and Milnacipran (Compound) resembles Levomilnacipran (Compound)
Iloprost may lead to a major life threatening interaction when taken with Edoxaban and Edoxaban may cause a moderate interaction that could exacerbate dise... |
DB00358 | DB01233 | 1,010 | 1,311 | [
"DDInter1140",
"DDInter1197"
] | Mefloquine | Metoclopramide | Malaria is a protozoan disease that places an enormous burden on human health in endemic areas around the world. The 2020 World Health Organization malaria report indicates a 60% decrease in the global malaria fatality rate between 2000 to 2019. Despite this, malaria remains a significant cause of morbidity and mortali... | Diabetic gastroparesis is a condition that causes frequent nausea and vomiting, which has a negative impact on quality of life and poses a significant burden on the healthcare system. Metoclopramide is a dopamine antagonist used to treat nausea and vomiting that may be associated with diabetic gastroparesis in addition... | Minor | 0 | [
[
[
1010,
23,
1311
]
],
[
[
1010,
24,
1151
],
[
1151,
40,
1311
]
],
[
[
1010,
25,
1425
],
[
1425,
40,
1311
]
],
[
[
1010,
25,
1401
],
[
14... | [
[
[
"Mefloquine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metoclopramide"
]
],
[
[
"Mefloquine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sunitinib"
],
[
... | Mefloquine may cause a moderate interaction that could exacerbate diseases when taken with Sunitinib and Sunitinib (Compound) resembles Metoclopramide (Compound)
Mefloquine may lead to a major life threatening interaction when taken with Cisapride and Cisapride (Compound) resembles Metoclopramide (Compound)
Mefloquine ... |
DB08932 | DB11730 | 1,398 | 351 | [
"DDInter1111",
"DDInter1588"
] | Macitentan | Ribociclib | Macitentan is a dual endothelin receptor antagonist used in the treatment of pulmonary arterial hypertension. It was first approved by the FDA in 2013. Macitentan differs from its predecessor [bosentan] due to its lower risk of hepatotoxicity. | Ribociclib is a selective cyclin-dependent kinase inhibitor, a class of drugs that help slow the progression of cancer by inhibiting two proteins called cyclin-dependent kinase 4 and 6 (CDK4/6). These proteins, when over-activated, can enable cancer cells to grow and divide too quickly. Targeting CDK4/6 with enhanced p... | Moderate | 1 | [
[
[
1398,
24,
351
]
],
[
[
1398,
24,
283
],
[
283,
62,
351
]
],
[
[
1398,
63,
597
],
[
597,
24,
351
]
],
[
[
1398,
24,
951
],
[
951,
... | [
[
[
"Macitentan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ribociclib"
]
],
[
[
"Macitentan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fedratinib"
],
[
... | Macitentan may cause a moderate interaction that could exacerbate diseases when taken with Fedratinib and Fedratinib may cause a minor interaction that can limit clinical effects when taken with Ribociclib
Macitentan may cause a moderate interaction that could exacerbate diseases when taken with Chloramphenicol and Chl... |
DB00612 | DB13142 | 1,121 | 841 | [
"DDInter216",
"DDInter274"
] | Bisoprolol | Calcium glubionate anhydrous | Bisoprolol is a cardioselective β1-adrenergic blocking agent used to treat high blood pressure.[A180472,L7219] It is considered a potent drug with a long-half life that can be used once daily to reduce the need for multiple doses of antihypertensive drugs. Bisoprolol is generally well tolerated, likely due to its β1-ad... | Calcium glubionate (or glubionate calcium) is a mineral supplement to prevent or treat low blood calcium levels in people who do not get enough calcium from their diets. | Moderate | 1 | [
[
[
1121,
24,
841
]
],
[
[
1121,
1,
887
],
[
887,
24,
841
]
],
[
[
1121,
62,
1152
],
[
1152,
24,
841
]
],
[
[
1121,
1,
887
],
[
887,
... | [
[
[
"Bisoprolol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Calcium glubionate anhydrous"
]
],
[
[
"Bisoprolol",
"{u} (Compound) resembles {v} (Compound)",
"Pindolol"
],
[
"Pindolol",
"{u} may c... | Bisoprolol (Compound) resembles Pindolol (Compound) and Pindolol may cause a moderate interaction that could exacerbate diseases when taken with Calcium glubionate anhydrous
Bisoprolol may cause a minor interaction that can limit clinical effects when taken with Liothyronine and Liothyronine may cause a moderate intera... |
DB00285 | DB00341 | 1,100 | 1,242 | [
"DDInter1927",
"DDInter343"
] | Venlafaxine | Cetirizine | Venlafaxine is an antidepressant and a serotonin and norepinephrine reuptake inhibitor (SNRI). Its active metabolite, [desvenlafaxine], works by blocking the reuptake of serotonin and norepinephrine, which are key neurotransmitters in mood regulation. Venlafaxine is officially approved to treat major depressive disorde... | Cetirizine, also commonly known as _Zyrtec_, is an orally active second-generation histamine H1 antagonist proven effective in the treatment of various allergic symptoms, such as sneezing, coughing, nasal congestion, hives, and other symptoms , . One of the most common uses for this drug is for a condition called _alle... | Moderate | 1 | [
[
[
1100,
24,
1242
]
],
[
[
1100,
24,
543
],
[
543,
63,
1242
]
],
[
[
1100,
21,
28900
],
[
28900,
60,
1242
]
],
[
[
1100,
24,
475
],
[
475... | [
[
[
"Venlafaxine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cetirizine"
]
],
[
[
"Venlafaxine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Loperamide"
],
[
... | Venlafaxine may cause a moderate interaction that could exacerbate diseases when taken with Loperamide and Loperamide may cause a moderate interaction that could exacerbate diseases when taken with Cetirizine
Venlafaxine (Compound) causes Abdominal pain (Side Effect) and Abdominal pain (Side Effect) is caused by Cetiri... |
DB06372 | DB09322 | 259 | 1,114 | [
"DDInter1594",
"DDInter1966"
] | Rilonacept | Zinc sulfate | Rilonacept is a dimeric fusion protein consisting of portions of IL-1R and the IL-1R accessory protein linked to the Fc portion of immunoglobulin G1. Rilonacept functions as an interleukin 1 inhibitor and is used in the treatment of CAPS, also known as cryopyrin-associated periodic syndromes, including familial cold au... | Zinc sulfate is the inorganic compound with the formula ZnSO4 and historically known as "white vitriol". It is on the World Health Organization's List of Essential Medicines, a list of the most important medication needed in a basic health system. | Minor | 0 | [
[
[
259,
23,
1114
]
],
[
[
259,
63,
66
],
[
66,
23,
1114
]
],
[
[
259,
24,
1093
],
[
1093,
62,
1114
]
],
[
[
259,
64,
1057
],
[
1057,
... | [
[
[
"Rilonacept",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Zinc sulfate"
]
],
[
[
"Rilonacept",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Efalizumab"
],
[
... | Rilonacept may cause a moderate interaction that could exacerbate diseases when taken with Efalizumab and Efalizumab may cause a minor interaction that can limit clinical effects when taken with Zinc sulfate
Rilonacept may cause a moderate interaction that could exacerbate diseases when taken with Ixekizumab and Ixekiz... |
DB00599 | DB06691 | 682 | 849 | [
"DDInter1795",
"DDInter1155"
] | Thiopental | Mepyramine | A barbiturate that is administered intravenously for the induction of general anesthesia or for the production of complete anesthesia of short duration. It is also used for hypnosis and for the control of convulsive states. It has been used in neurosurgical patients to reduce increased intracranial pressure. It does no... | Mepyramine, or pyrilamine, targets the H1 receptor. It is a first generation antihistamine. However, it rapidly permeates the brain and so often causes drowsiness as a side effect. It has been found in over-the-counter combination products for colds and menstrual symptoms, but is considered to be an unapproved prescrip... | Moderate | 1 | [
[
[
682,
24,
849
]
],
[
[
682,
63,
1594
],
[
1594,
24,
849
]
],
[
[
682,
24,
770
],
[
770,
24,
849
]
],
[
[
682,
24,
1074
],
[
1074,
... | [
[
[
"Thiopental",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mepyramine"
]
],
[
[
"Thiopental",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxylamine"
],
[
... | Thiopental may cause a moderate interaction that could exacerbate diseases when taken with Doxylamine and Doxylamine may cause a moderate interaction that could exacerbate diseases when taken with Mepyramine
Thiopental may cause a moderate interaction that could exacerbate diseases when taken with Thalidomide and Thali... |
DB00047 | DB00388 | 176 | 1,636 | [
"DDInter932",
"DDInter1453"
] | Insulin glargine | Phenylephrine | Insulin glargine is a long-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes. Insulin is typically prescribed for the management of diabetes mellitus to mimic the activity of endogenously produced human insulin, a peptide hormone produced by beta cells of the pancreas t... | Phenylephrine is an alpha-1 adrenergic receptor agonist used to treat hypotension,[L9416,L9410] dilate the pupil, and induce local vasoconstriction. The action of phenylephrine, or neo-synephrine, was first described in literature in the 1930s. Phenylephrine was granted FDA approval in 1939. | Moderate | 1 | [
[
[
176,
24,
1636
]
],
[
[
176,
24,
874
],
[
874,
40,
1636
]
],
[
[
176,
24,
1148
],
[
1148,
63,
1636
]
],
[
[
176,
24,
1399
],
[
1399,
... | [
[
[
"Insulin glargine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenylephrine"
]
],
[
[
"Insulin glargine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Epinephrine"... | Insulin glargine may cause a moderate interaction that could exacerbate diseases when taken with Epinephrine and Epinephrine (Compound) resembles Phenylephrine (Compound)
Insulin glargine may cause a moderate interaction that could exacerbate diseases when taken with Isoprenaline and Isoprenaline may cause a moderate i... |
DB06779 | DB11793 | 365 | 738 | [
"DDInter470",
"DDInter1297"
] | Dalteparin | Niraparib | Dalteparin, a low molecular weight heparin (LMWH) prepared by nitrous acid degradation of unfractionated heparin of porcine intestinal mucosa origin, is an anticoagulant. It is composed of strongly acidic sulphated polysaccharide chains with an average molecular weight of 5000 and about 90% of the material within the r... | Niraparib is an orally active poly (ADP-ribose) polymerase (PARP) inhibitor. By blocking the enzymes responsible for DNA repair, niraparib induces cytotoxicity in cancer cells. Niraparib is selective towards PARP-1 and PARP-2. First approved by the FDA on March 27, 2017, niraparib is used to treat epithelial ovarian, f... | Moderate | 1 | [
[
[
365,
24,
738
]
],
[
[
365,
64,
1213
],
[
1213,
24,
738
]
],
[
[
365,
63,
443
],
[
443,
24,
738
]
],
[
[
365,
25,
397
],
[
397,
2... | [
[
[
"Dalteparin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Niraparib"
]
],
[
[
"Dalteparin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dasatinib"
],
[
"Dasatinib",
... | Dalteparin may lead to a major life threatening interaction when taken with Dasatinib and Dasatinib may cause a moderate interaction that could exacerbate diseases when taken with Niraparib
Dalteparin may cause a moderate interaction that could exacerbate diseases when taken with Spironolactone and Spironolactone may c... |
DB00398 | DB14509 | 79 | 1,399 | [
"DDInter1702",
"DDInter1081"
] | Sorafenib | Lithium carbonate | Sorafenib is a bi-aryl urea and an oral multikinase inhibitor. It targets cell surface tyrosine kinase receptors and downstream intracellular kinases that are implicated in tumour cell proliferation and tumour angiogenesis. First approved by the FDA and European Commission in 2007 for the treatment of hepatocellular ca... | Lithium has been used to treat manic episodes since the 19th century. Though it is widely used, its mechanism of action is still unknown[FDA Label][A14585,A176642,A176651,L5843]. Lithium carbonate has a narrow therapeutic range and so careful monitoring is required to avoid adverse effects[FDA Label]. | Moderate | 1 | [
[
[
79,
24,
1399
]
],
[
[
79,
24,
1374
],
[
1374,
24,
1399
]
],
[
[
79,
63,
1010
],
[
1010,
24,
1399
]
],
[
[
79,
23,
112
],
[
112,
... | [
[
[
"Sorafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lithium carbonate"
]
],
[
[
"Sorafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Abiraterone"
],
... | Sorafenib may cause a moderate interaction that could exacerbate diseases when taken with Abiraterone and Abiraterone may cause a moderate interaction that could exacerbate diseases when taken with Lithium carbonate
Sorafenib may cause a moderate interaction that could exacerbate diseases when taken with Mefloquine and... |
DB00358 | DB09083 | 1,010 | 880 | [
"DDInter1140",
"DDInter996"
] | Mefloquine | Ivabradine | Malaria is a protozoan disease that places an enormous burden on human health in endemic areas around the world. The 2020 World Health Organization malaria report indicates a 60% decrease in the global malaria fatality rate between 2000 to 2019. Despite this, malaria remains a significant cause of morbidity and mortali... | Ivabradine is a novel heart rate lowering medicine for the symptomatic management of stable angina pectoralis and symptomatic chronic heart failure. Ivabradine, brand name Corlanor, was approved by the FDA in April 2015 for the treatment of chronic heart failure in patients with an ejection fraction of ≤35%, in sinus r... | Major | 2 | [
[
[
1010,
25,
880
]
],
[
[
1010,
24,
480
],
[
480,
24,
880
]
],
[
[
1010,
24,
159
],
[
159,
63,
880
]
],
[
[
1010,
63,
1051
],
[
1051,
... | [
[
[
"Mefloquine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ivabradine"
]
],
[
[
"Mefloquine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Formoterol"
],
[
"Formoterol... | Mefloquine may cause a moderate interaction that could exacerbate diseases when taken with Formoterol and Formoterol may cause a moderate interaction that could exacerbate diseases when taken with Ivabradine
Mefloquine may cause a moderate interaction that could exacerbate diseases when taken with Larotrectinib and Lar... |
DB00570 | DB00916 | 147 | 112 | [
"DDInter1936",
"DDInter1202"
] | Vinblastine | Metronidazole | Antitumor alkaloid isolated from Vinca rosea. (Merck, 11th ed.) | Metronidazole is a commonly used antibiotic, belonging to the nitroimidazole class of antibiotics. It is frequently used to treat gastrointestinal infections as well as trichomoniasis and giardiasis, and amebiasis which are parasitic infections.[A181036,A181039] Metronidazole has been used as an antibiotic for several ... | Moderate | 1 | [
[
[
147,
24,
112
]
],
[
[
147,
24,
458
],
[
458,
40,
112
]
],
[
[
147,
6,
8374
],
[
8374,
45,
112
]
],
[
[
147,
21,
28640
],
[
28640,
... | [
[
[
"Vinblastine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metronidazole"
]
],
[
[
"Vinblastine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tinidazole"
],
... | Vinblastine may cause a moderate interaction that could exacerbate diseases when taken with Tinidazole and Tinidazole (Compound) resembles Metronidazole (Compound)
Vinblastine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Metronidazole (Compound)
Vinblastine (Compound) causes Depression (Side Effect) and... |
DB00312 | DB09330 | 1,023 | 985 | [
"DDInter1423",
"DDInter1352"
] | Pentobarbital | Osimertinib | A short-acting barbiturate that is effective as a sedative and hypnotic (but not as an anti-anxiety) agent and is usually given orally. It is prescribed more frequently for sleep induction than for sedation but, like similar agents, may lose its effectiveness by the second week of continued administration. (From AMA Dr... | Osimertinib is an oral, third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) drug developed by AstraZeneca Pharmaceuticals.[A7926,L43453] Its use is indicated for the treatment of metastatic non-small cell lung cancer (NSCLC) in cases where tumour EGFR expression is positive for the ... | Moderate | 1 | [
[
[
1023,
24,
985
]
],
[
[
1023,
62,
168
],
[
168,
23,
985
]
],
[
[
1023,
24,
112
],
[
112,
23,
985
]
],
[
[
1023,
24,
1478
],
[
1478,
... | [
[
[
"Pentobarbital",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Osimertinib"
]
],
[
[
"Pentobarbital",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Bortezomib"
],
... | Pentobarbital may cause a minor interaction that can limit clinical effects when taken with Bortezomib and Bortezomib may cause a minor interaction that can limit clinical effects when taken with Osimertinib
Pentobarbital may cause a moderate interaction that could exacerbate diseases when taken with Metronidazole and ... |
DB01259 | DB12267 | 392 | 1,476 | [
"DDInter1024",
"DDInter233"
] | Lapatinib | Brigatinib | Lapatinib is an anti-cancer drug developed by GlaxoSmithKline (GSK) as a treatment for solid tumours such as breast and lung cancer. It was approved by the FDA on March 13, 2007, for use in patients with advanced metastatic breast cancer in conjunction with the chemotherapy drug capecitabine. Lapatinib is a human epide... | Brigatinib, originally named AP26113, is a reversible dual inhibitor of anaplastic lymphoma kinase (ALK) and epidermal growth factor receptor (EGFR). It presents selectivity against the mutant forms of EGFR compared to the wild-type. It also exhibits selectivity against 9 different Crizotinib-resistant mutants of the E... | Moderate | 1 | [
[
[
392,
24,
1476
]
],
[
[
392,
24,
1612
],
[
1612,
23,
1476
]
],
[
[
392,
23,
1135
],
[
1135,
23,
1476
]
],
[
[
392,
25,
230
],
[
230,
... | [
[
[
"Lapatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brigatinib"
]
],
[
[
"Lapatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fostemsavir"
],
[
... | Lapatinib may cause a moderate interaction that could exacerbate diseases when taken with Fostemsavir and Fostemsavir may cause a minor interaction that can limit clinical effects when taken with Brigatinib
Lapatinib may cause a minor interaction that can limit clinical effects when taken with Naloxegol and Naloxegol m... |
DB09054 | DB11988 | 384 | 270 | [
"DDInter905",
"DDInter1321"
] | Idelalisib | Ocrelizumab | Idelalisib is a phosphoinositide 3-kinase inhibitor indicated in the treatment of chronic lymphocytic leukemia (CLL), relapsed follicular B-cell non-Hodgkin lymphoma (FL), and relapsed small lymphocytic lymphoma (SLL). For the treatment of relapsed CLL, it is currently indicated as a second-line agent in combination wi... | Ocrelizumab is a CD20-directed cytolytic antibody indicated for the treatment of patients with primary progressive or relapsing forms of multiple sclerosis (MS). It is a second-generation recombinant humanized monoclonal IgG1 antibody that selectively targets B-cells that express the CD20 antigen. Compared to non-human... | Moderate | 1 | [
[
[
384,
24,
270
]
],
[
[
384,
25,
1060
],
[
1060,
63,
270
]
],
[
[
384,
64,
134
],
[
134,
24,
270
]
],
[
[
384,
25,
1019
],
[
1019,
... | [
[
[
"Idelalisib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ocrelizumab"
]
],
[
[
"Idelalisib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Enfortumab vedotin"
],
[
"E... | Idelalisib may lead to a major life threatening interaction when taken with Enfortumab vedotin and Enfortumab vedotin may cause a moderate interaction that could exacerbate diseases when taken with Ocrelizumab
Idelalisib may lead to a major life threatening interaction when taken with Vinorelbine and Vinorelbine may ca... |
DB06414 | DB09330 | 655 | 985 | [
"DDInter703",
"DDInter1352"
] | Etravirine | Osimertinib | Etravirine is an antiretroviral agent more specifically classified as a Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI). Etraverine is used clinically for the treatment of human immunodeficiency virus type 1 (HIV-1) infection. On January 18, 2007, the FDA granted accelerated approved for the use of etravirine 10... | Osimertinib is an oral, third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) drug developed by AstraZeneca Pharmaceuticals.[A7926,L43453] Its use is indicated for the treatment of metastatic non-small cell lung cancer (NSCLC) in cases where tumour EGFR expression is positive for the ... | Moderate | 1 | [
[
[
655,
24,
985
]
],
[
[
655,
62,
168
],
[
168,
23,
985
]
],
[
[
655,
63,
112
],
[
112,
23,
985
]
],
[
[
655,
24,
1478
],
[
1478,
2... | [
[
[
"Etravirine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Osimertinib"
]
],
[
[
"Etravirine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Bortezomib"
],
[
... | Etravirine may cause a minor interaction that can limit clinical effects when taken with Bortezomib and Bortezomib may cause a minor interaction that can limit clinical effects when taken with Osimertinib
Etravirine may cause a moderate interaction that could exacerbate diseases when taken with Metronidazole and Metron... |
DB00261 | DB11718 | 702 | 927 | [
"DDInter93",
"DDInter640"
] | Anagrelide | Encorafenib | Anagrelide is a platelet-reducing agent used to lower dangerously elevated platelet levels (i.e. to treat thrombocythemia) in patients with myeloproliferative neoplasms. It is an oral imidazoquinazoline that was first approved for use in the US in 1997. It appears to carry a better response rate than other thrombocythe... | Encorafenib, also known as _BRAFTOVI_, is a kinase inhibitor. Encorafenib inhibits BRAF gene, which encodes for B-raf protein, which is a proto-oncogene involved in various genetic mutations. This protein plays a role in regulating the MAP kinase/ERK signaling pathway, which impacts cell division, differentiation, and ... | Major | 2 | [
[
[
702,
25,
927
]
],
[
[
702,
23,
112
],
[
112,
23,
927
]
],
[
[
702,
24,
720
],
[
720,
24,
927
]
],
[
[
702,
25,
216
],
[
216,
24,... | [
[
[
"Anagrelide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Encorafenib"
]
],
[
[
"Anagrelide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metronid... | Anagrelide may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Encorafenib
Anagrelide may cause a moderate interaction that could exacerbate diseases when taken with Mineral oil and Mi... |
DB01377 | DB09407 | 1,283 | 853 | [
"DDInter1119",
"DDInter1114"
] | Magnesium oxide | Magnesium chloride | Magnesium oxide is an inorganic compound that occurs in nature as the mineral periclase. In aqueous media combines quickly with water to form magnesium hydroxide. It is used as an antacid and mild laxative and has many nonmedicinal uses. | Magnesium chloride salts are highly soluble in water and the hydrated form of magnesium chloride can be extracted from brine or sea water. | Moderate | 1 | [
[
[
1283,
24,
853
]
],
[
[
1283,
63,
1539
],
[
1539,
24,
853
]
],
[
[
1283,
24,
460
],
[
460,
63,
853
]
],
[
[
1283,
24,
1196
],
[
1196,
... | [
[
[
"Magnesium oxide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium chloride"
]
],
[
[
"Magnesium oxide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ofloxacin... | Magnesium oxide may cause a moderate interaction that could exacerbate diseases when taken with Ofloxacin and Ofloxacin may cause a moderate interaction that could exacerbate diseases when taken with Magnesium chloride
Magnesium oxide may cause a moderate interaction that could exacerbate diseases when taken with Magne... |
DB00758 | DB01124 | 1,347 | 1,411 | [
"DDInter413",
"DDInter1828"
] | Clopidogrel | Tolbutamide | Clopidogrel is a prodrug of a platelet inhibitor used to reduce the risk of myocardial infarction and stroke.[A180508,L7213] Clopidogrel is indicated to reduce the risk of myocardial infarction for patients with non-ST elevated acute coronary syndrome (ACS), patients with ST-elevated myocardial infarction, and in recen... | Tolbutamide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It is structurally similar to acetohexamide, chlorpropamide and tolazamide and belongs to the sulfonylurea class of insulin secretagogues, which act by stimulating β cells of the pancreas to release... | Minor | 0 | [
[
[
1347,
23,
1411
]
],
[
[
1347,
62,
245
],
[
245,
40,
1411
]
],
[
[
1347,
6,
10215
],
[
10215,
45,
1411
]
],
[
[
1347,
7,
6314
],
[
6314... | [
[
[
"Clopidogrel",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Tolbutamide"
]
],
[
[
"Clopidogrel",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Glimepiride"
],
[
... | Clopidogrel may cause a minor interaction that can limit clinical effects when taken with Glimepiride and Glimepiride (Compound) resembles Tolbutamide (Compound)
Clopidogrel (Compound) binds CYP2C19 (Gene) and CYP2C19 (Gene) is bound by Tolbutamide (Compound)
Clopidogrel (Compound) upregulates TLR4 (Gene) and TLR4 (Gen... |
DB01073 | DB01235 | 1,488 | 1,191 | [
"DDInter745",
"DDInter1054"
] | Fludarabine | Levodopa | Fludarabine is a chemotherapeutic agent used in the treatment of hematological malignancies. It is commonly marketed under the brand name Fludara. | Levodopa is a prodrug of dopamine that is administered to patients with Parkinson's due to its ability to cross the blood-brain barrier[Label]. Levodopa can be metabolised to dopamine on either side of the blood-brain barrier and so it is generally administered with a dopa decarboxylase inhibitor like carbidopa to prev... | Moderate | 1 | [
[
[
1488,
24,
1191
]
],
[
[
1488,
63,
1307
],
[
1307,
40,
1191
]
],
[
[
1488,
21,
28936
],
[
28936,
60,
1191
]
],
[
[
1488,
63,
63
],
[
63... | [
[
[
"Fludarabine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levodopa"
]
],
[
[
"Fludarabine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Melphalan"
],
[
... | Fludarabine may cause a moderate interaction that could exacerbate diseases when taken with Melphalan and Melphalan (Compound) resembles Levodopa (Compound)
Fludarabine (Compound) causes Hyperhidrosis (Side Effect) and Hyperhidrosis (Side Effect) is caused by Levodopa (Compound)
Fludarabine may cause a moderate interac... |
DB00227 | DB00549 | 1,463 | 522 | [
"DDInter1098",
"DDInter1955"
] | Lovastatin | Zafirlukast | Lovastatin, also known as the brand name product Mevacor, is a lipid-lowering drug and fungal metabolite derived synthetically from a fermentation product of _Aspergillus terreus_. Originally named Mevinolin, lovastatin belongs to the statin class of medications, which are used to lower the risk of cardiovascular disea... | Zafirlukast is an oral leukotriene receptor antagonist (LTRA) for the maintenance treatment of asthma, often used in conjunction with an inhaled steroid and/or long-acting bronchodilator. It is available as a tablet and is usually dosed twice daily. Another leukotriene receptor antagonist is montelukast (Singulair), wh... | Moderate | 1 | [
[
[
1463,
24,
522
]
],
[
[
1463,
6,
8374
],
[
8374,
45,
522
]
],
[
[
1463,
21,
29226
],
[
29226,
60,
522
]
],
[
[
1463,
63,
168
],
[
168,
... | [
[
[
"Lovastatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Zafirlukast"
]
],
[
[
"Lovastatin",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)"... | Lovastatin (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Zafirlukast (Compound)
Lovastatin (Compound) causes Sinusitis (Side Effect) and Sinusitis (Side Effect) is caused by Zafirlukast (Compound)
Lovastatin may cause a moderate interaction that could exacerbate diseases when taken with Bortezomib and Bo... |
DB00261 | DB01115 | 702 | 336 | [
"DDInter93",
"DDInter1291"
] | Anagrelide | Nifedipine | Anagrelide is a platelet-reducing agent used to lower dangerously elevated platelet levels (i.e. to treat thrombocythemia) in patients with myeloproliferative neoplasms. It is an oral imidazoquinazoline that was first approved for use in the US in 1997. It appears to carry a better response rate than other thrombocythe... | Nifedipine, or BAY a 1040, is a first generation dihydropyridine L-type calcium channel blocker, similar to [nicardipine].[A190210,A190273,A175390,L11383] Nifedipine was developed by Bayer and first described in the literature, along with other dihydropyridines, in 1972.[A175390,A190276] Since nifedipine's development,... | Moderate | 1 | [
[
[
702,
24,
336
]
],
[
[
702,
6,
7950
],
[
7950,
45,
336
]
],
[
[
702,
18,
7933
],
[
7933,
46,
336
]
],
[
[
702,
18,
10375
],
[
10375,
... | [
[
[
"Anagrelide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nifedipine"
]
],
[
[
"Anagrelide",
"{u} (Compound) binds {v} (Gene)",
"CYP1A2"
],
[
"CYP1A2",
"{u} (Gene) is bound by {v} (Compound)",... | Anagrelide (Compound) binds CYP1A2 (Gene) and CYP1A2 (Gene) is bound by Nifedipine (Compound)
Anagrelide (Compound) downregulates DDX42 (Gene) and DDX42 (Gene) is upregulated by Nifedipine (Compound)
Anagrelide (Compound) downregulates RPS4Y1 (Gene) and RPS4Y1 (Gene) is downregulated by Nifedipine (Compound)
Anagrelide... |
DB00277 | DB14724 | 1,031 | 48 | [
"DDInter1791",
"DDInter634"
] | Theophylline | Emapalumab | A methylxanthine derivative from tea with diuretic, smooth muscle relaxant, bronchial dilation, cardiac and central nervous system stimulant activities. Mechanistically, theophylline acts as a phosphodiesterase inhibitor, adenosine receptor blocker, and histone deacetylase activator. Theophylline is marketed under seve... | Emapalumab, also known as NI-0501, is a fully human monoclonal antibody that targets interferon gamma. Emapalumab development was sponsored by NovImmune SA, further developed by Sobi and FDA approved on November 20, 2018.[A38676, L4840] The approval of emapalumab was followed by the designation of orphan drug, priority... | Moderate | 1 | [
[
[
1031,
24,
48
]
],
[
[
1031,
24,
1197
],
[
1197,
24,
48
]
],
[
[
1031,
63,
362
],
[
362,
24,
48
]
],
[
[
1031,
25,
143
],
[
143,
... | [
[
[
"Theophylline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Emapalumab"
]
],
[
[
"Theophylline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Norethisterone"
],
... | Theophylline may cause a moderate interaction that could exacerbate diseases when taken with Norethisterone and Norethisterone may cause a moderate interaction that could exacerbate diseases when taken with Emapalumab
Theophylline may cause a moderate interaction that could exacerbate diseases when taken with Phenytoin... |
DB01575 | DB14881 | 1,054 | 180 | [
"DDInter1005",
"DDInter1329"
] | Kaolin | Oliceridine | Kaolin is a layered silicate mineral. Kaolin is used in ceramics, medicine, coated paper, as a food additive, in toothpaste, as a light diffusing material in white incandescent light bulbs, and in cosmetics. Until the early 1990s it was the active substance of anti-diarrhoea medicine Kaopectate. | Severe acute pain occurs through nociceptive signalling involving both ascending and descending spinal pathways, in which nerve conductance is mediated in part by the action of opioid receptors.[A218041, A218046] Opioid receptors are seven-transmembrane G-protein-coupled receptors (GPCRs), of which the μ-opioid recepto... | Moderate | 1 | [
[
[
1054,
24,
180
]
],
[
[
1054,
63,
85
],
[
85,
24,
180
]
],
[
[
1054,
24,
407
],
[
407,
24,
180
]
],
[
[
1054,
24,
1487
],
[
1487,
... | [
[
[
"Kaolin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Oliceridine"
]
],
[
[
"Kaolin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Atropine"
],
[
"Atro... | Kaolin may cause a moderate interaction that could exacerbate diseases when taken with Atropine and Atropine may cause a moderate interaction that could exacerbate diseases when taken with Oliceridine
Kaolin may cause a moderate interaction that could exacerbate diseases when taken with Opium and Opium may cause a mode... |
DB00637 | DB08871 | 1,557 | 36 | [
"DDInter128",
"DDInter666"
] | Astemizole | Eribulin | Astemizole is a long-acting, non-sedating second generation antihistamine used in the treatment of allergy symptoms. It was withdrawn from market by the manufacturer in 1999 due to the potential to cause arrhythmias at high doses, especially when when taken with CYP inhibitors or grapefruit juice. | Eribulin is a microtubule inhibitor indicated for the treatment of patients with metastatic breast cancer who have previously received at least two chemotherapeutic regimens for the treatment of metastatic disease. Eribulin was isolated from the marine sponge Halichondria okadai. Eribulin is also being investigated for... | Moderate | 1 | [
[
[
1557,
24,
36
]
],
[
[
1557,
23,
1247
],
[
1247,
23,
36
]
],
[
[
1557,
24,
519
],
[
519,
24,
36
]
],
[
[
1557,
64,
1424
],
[
1424,
... | [
[
[
"Astemizole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Eribulin"
]
],
[
[
"Astemizole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Sulfamethoxazole"
],
[
... | Astemizole may cause a minor interaction that can limit clinical effects when taken with Sulfamethoxazole and Sulfamethoxazole may cause a minor interaction that can limit clinical effects when taken with Eribulin
Astemizole may cause a moderate interaction that could exacerbate diseases when taken with Paliperidone an... |
DB00620 | DB11640 | 175 | 1,267 | [
"DDInter1855",
"DDInter64"
] | Triamcinolone | Amifampridine | Triamcinolone is a corticosteroid used to treat various inflammatory conditions in the body from allergic rhinitis to acute exacerbations of multiple sclerosis. Triamcinolone can be used as a one time adjunct treatment of osteoarthritic knee pain, or first line as a topical treatment of corticosteroid responsive dermat... | Amifampridine, or 3,4-diaminopyridine (3,4-DAP), is a quaternary ammonium compound that blocks presynaptic potassium channels, and subsequently prolongs the action potential and increases presynaptic calcium concentrations . It was first discovered in Scotland in the 1970s and its clinical effectiveness for neuromuscul... | Moderate | 1 | [
[
[
175,
24,
1267
]
],
[
[
175,
40,
1220
],
[
1220,
24,
1267
]
],
[
[
175,
24,
61
],
[
61,
24,
1267
]
],
[
[
175,
63,
1648
],
[
1648,
... | [
[
[
"Triamcinolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Amifampridine"
]
],
[
[
"Triamcinolone",
"{u} (Compound) resembles {v} (Compound)",
"Dexamethasone"
],
[
"Dexamethasone",
"{u} may ... | Triamcinolone (Compound) resembles Dexamethasone (Compound) and Dexamethasone may cause a moderate interaction that could exacerbate diseases when taken with Amifampridine
Triamcinolone may cause a moderate interaction that could exacerbate diseases when taken with Edrophonium and Edrophonium may cause a moderate inter... |
DB08868 | DB09073 | 1,011 | 951 | [
"DDInter737",
"DDInter1379"
] | Fingolimod | Palbociclib | Multiple sclerosis, or MS, is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Fingolimod is a sphingosine 1-phosphate receptor modulator for the treatment of relapsing-remitting multiple sclerosis. It was developed by Novartis and initially appro... | Palbociclib is a piperazine pyridopyrimidine that acts in the cell cycle machinery. It is a second generation cyclin-dependent kinase inhibitor selected from a group of pyridopyrimidine compounds due to its favorable physical and pharmaceutical properties. Palbociclib was developed by Pfizer Inc after the discovery tha... | Major | 2 | [
[
[
1011,
25,
951
]
],
[
[
1011,
64,
318
],
[
318,
23,
951
]
],
[
[
1011,
63,
479
],
[
479,
23,
951
]
],
[
[
1011,
24,
496
],
[
496,
... | [
[
[
"Fingolimod",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Palbociclib"
]
],
[
[
"Fingolimod",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Escitalopram"
],
[
"Escitalopram",
"... | Fingolimod may lead to a major life threatening interaction when taken with Escitalopram and Escitalopram may cause a minor interaction that can limit clinical effects when taken with Palbociclib
Fingolimod may cause a moderate interaction that could exacerbate diseases when taken with Donepezil and Donepezil may cause... |
DB00604 | DB00938 | 1,425 | 455 | [
"DDInter385",
"DDInter1635"
] | Cisapride | Salmeterol | In many countries (including Canada) cisapride has been either withdrawn or has had its indications limited due to reports about long QT syndrome due to cisapride, which predisposes to arrhythmias. The FDA issued a warning letter regarding this risk to health care professionals and patients. | Salmeterol is a long-acting beta-2 adrenergic receptor agonist drug that is currently prescribed for the treatment of asthma and chronic obstructive pulmonary disease COPD.[L11545,L11548,L11551,L11554,L11557] It has a longer duration of action than the short-acting beta-2 adrenergic receptor agonist, [salbutamol]. Salm... | Moderate | 1 | [
[
[
1425,
24,
455
]
],
[
[
1425,
24,
688
],
[
688,
63,
455
]
],
[
[
1425,
25,
371
],
[
371,
63,
455
]
],
[
[
1425,
6,
6799
],
[
6799,
... | [
[
[
"Cisapride",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Salmeterol"
]
],
[
[
"Cisapride",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Salbutamol"
],
[
... | Cisapride may cause a moderate interaction that could exacerbate diseases when taken with Salbutamol and Salbutamol may cause a moderate interaction that could exacerbate diseases when taken with Salmeterol
Cisapride may lead to a major life threatening interaction when taken with Propafenone and Propafenone may cause ... |
DB00655 | DB08881 | 559 | 868 | [
"DDInter682",
"DDInter1925"
] | Estrone | Vemurafenib | Estrone, one of the major mammalian estrogens, is an aromatized C18 steroid with a 3-hydroxyl group and a 17-ketone. It is produced in vivo from androstenedione or from testosterone via estradiol. It is produced primarily in the ovaries, placenta, and in peripheral tissues (especially adipose tissue) through conversion... | Vemurafenib is a competitive kinase inhibitor with activity against BRAF kinase with mutations like V600E. It exerts its function by binding to the ATP-binding domain of the mutant BRAF. Vemurafenib was co-developed by Roche and Plexxikon and it obtained its FDA approval on August 17, 2011, under the company Hoffmann L... | Moderate | 1 | [
[
[
559,
24,
868
]
],
[
[
559,
6,
8374
],
[
8374,
45,
868
]
],
[
[
559,
18,
10375
],
[
10375,
57,
868
]
],
[
[
559,
21,
28658
],
[
28658,
... | [
[
[
"Estrone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vemurafenib"
]
],
[
[
"Estrone",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
... | Estrone (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Vemurafenib (Compound)
Estrone (Compound) downregulates RPS4Y1 (Gene) and RPS4Y1 (Gene) is downregulated by Vemurafenib (Compound)
Estrone (Compound) causes Vomiting (Side Effect) and Vomiting (Side Effect) is caused by Vemurafenib (Compound)
Estrone ... |
DB00099 | DB00488 | 440 | 196 | [
"DDInter735",
"DDInter57"
] | Filgrastim | Altretamine | Filgrastim is a short-acting recombinant, non-pegylated human granulocyte colony-stimulating factor (G-CSF) analog produced by recombinant DNA technology. It has an amino acid sequence identical to endogenous G-CSF, but it is non-glycosylated unlike the endogenous G-CSF and has an N-terminal methionine added in the seq... | An alkylating agent proposed as an antineoplastic. It also acts as a chemosterilant for male houseflies and other insects. | Moderate | 1 | [
[
[
440,
24,
196
]
],
[
[
440,
24,
4
],
[
4,
63,
196
]
],
[
[
440,
63,
599
],
[
599,
24,
196
]
],
[
[
440,
25,
1064
],
[
1064,
25,
... | [
[
[
"Filgrastim",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Altretamine"
]
],
[
[
"Filgrastim",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Omacetaxine mepesuccinate"... | Filgrastim may cause a moderate interaction that could exacerbate diseases when taken with Omacetaxine mepesuccinate and Omacetaxine mepesuccinate may cause a moderate interaction that could exacerbate diseases when taken with Altretamine
Filgrastim may cause a moderate interaction that could exacerbate diseases when t... |
DB01281 | DB11248 | 881 | 1,193 | [
"DDInter5",
"DDInter1965"
] | Abatacept | Zinc gluconate | Abatacept is a soluble fusion protein, which links the extracellular domain of human cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) to the modified Fc (hinge, CH2, and CH3 domains) portion of human immunoglobulin G1 (IgG1).[L20504,L42715] Structurally, abatacept is a glycosylated fusion protein with a MALDI-MS mo... | Zinc gluconate is a zinc salt of gluconic acid comprised of two gluconic acid molecules for each zinc cation (2+). Zinc gluconate is a generally recognized as safe (GRAS) substance by FDA . It is available as a trace mineral supplement and over the counter as a lozenge form for a reduced duration of common colds and wi... | Minor | 0 | [
[
[
881,
23,
1193
]
],
[
[
881,
25,
725
],
[
725,
62,
1193
]
],
[
[
881,
24,
1531
],
[
1531,
23,
1193
]
],
[
[
881,
24,
270
],
[
270,
... | [
[
[
"Abatacept",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Zinc gluconate"
]
],
[
[
"Abatacept",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Satralizumab"
],
[
"Satraliz... | Abatacept may lead to a major life threatening interaction when taken with Satralizumab and Satralizumab may cause a minor interaction that can limit clinical effects when taken with Zinc gluconate
Abatacept may cause a moderate interaction that could exacerbate diseases when taken with Canakinumab and Canakinumab may ... |
DB00603 | DB06717 | 303 | 875 | [
"DDInter1137",
"DDInter778"
] | Medroxyprogesterone acetate | Fosaprepitant | Medroxyprogesterone acetate (MPA) is a [progesterone] derivative that is more resistant to metabolism for improved pharmacokinetic properties. MPA can be use to treat secondary amenorrhea, endometrial hyperplasia, abnormal uterine bleeding, osteoporosis, vasomotor symptoms in menopause, vulvar and vaginal atrophy, prev... | Fosaprepitant is an intravenously administered antiemetic drug. It is a prodrug of Aprepitant. It aids in the prevention of acute and delayed nausea and vomiting associated with chemotherapy treatment. | Moderate | 1 | [
[
[
303,
24,
875
]
],
[
[
303,
24,
723
],
[
723,
1,
875
]
],
[
[
303,
21,
29180
],
[
29180,
60,
875
]
],
[
[
303,
64,
1101
],
[
1101,
... | [
[
[
"Medroxyprogesterone acetate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fosaprepitant"
]
],
[
[
"Medroxyprogesterone acetate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}... | Medroxyprogesterone acetate may cause a moderate interaction that could exacerbate diseases when taken with Aprepitant and Aprepitant (Compound) resembles Fosaprepitant (Compound)
Medroxyprogesterone acetate (Compound) causes Abdominal distension (Side Effect) and Abdominal distension (Side Effect) is caused by Fosapre... |
DB09079 | DB12364 | 1,496 | 1,421 | [
"DDInter1296",
"DDInter200"
] | Nintedanib | Betrixaban | Nintedanib is a small molecule kinase inhibitor used in the treatment of pulmonary fibrosis, systemic sclerosis-associated interstitial lung disease, and non-small cell lung cancer (NSCLC).[L8453,L8459] It was first approved for use in the United States in 2014. Within the spectrum of idiopathic pulmonary fibrosis trea... | Betrixaban is a non-vitamin K oral anticoagulant whose action is driven by the competitive and reversible inhibition of the factor Xa . It was selected among all lead compounds due to its low hERG channel affinity while sustaining its factor Xa inhibition capacity . Betrixaban, now developed by Portola Pharmaceuticals ... | Moderate | 1 | [
[
[
1496,
24,
1421
]
],
[
[
1496,
25,
1017
],
[
1017,
24,
1421
]
],
[
[
1496,
64,
759
],
[
759,
24,
1421
]
],
[
[
1496,
24,
1097
],
[
1097... | [
[
[
"Nintedanib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Betrixaban"
]
],
[
[
"Nintedanib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lorlatinib"
],
[
"Lorlatinib... | Nintedanib may lead to a major life threatening interaction when taken with Lorlatinib and Lorlatinib may cause a moderate interaction that could exacerbate diseases when taken with Betrixaban
Nintedanib may lead to a major life threatening interaction when taken with Primidone and Primidone may cause a moderate intera... |
DB00444 | DB10343 | 63 | 962 | [
"DDInter1765",
"DDInter160"
] | Teniposide | Bacillus calmette-guerin substrain tice live antigen | Teniposide is a semisynthetic derivative of podophyllotoxin that exhibits antitumor activity. Teniposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent cells ... | Bacillus calmette-guerin substrain tice live antigen is a vaccine containing attenuated live culture preparation of the Bacillus of Calmette and Guerin (BCG) strain of *Mycobacterium bovis* for percutaneous use. It is administered to prevent the development of tuberculosis. | Major | 2 | [
[
[
63,
25,
962
]
],
[
[
63,
64,
1057
],
[
1057,
25,
962
]
],
[
[
63,
24,
1213
],
[
1213,
25,
962
]
],
[
[
63,
24,
270
],
[
270,
64,... | [
[
[
"Teniposide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Bacillus calmette-guerin substrain tice live antigen"
]
],
[
[
"Teniposide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Etanercept"
... | Teniposide may lead to a major life threatening interaction when taken with Etanercept and Etanercept may lead to a major life threatening interaction when taken with Bacillus calmette-guerin substrain tice live antigen
Teniposide may cause a moderate interaction that could exacerbate diseases when taken with Dasatinib... |
DB00207 | DB06595 | 1,570 | 1,491 | [
"DDInter157",
"DDInter1214"
] | Azithromycin | Midostaurin | Azithromycin is a broad-spectrum macrolide antibiotic with a long half-life and a high degree of tissue penetration. It was initially approved by the FDA in 1991. It is primarily used for the treatment of respiratory, enteric and genitourinary infections and may be used instead of other macrolides for some sexually tra... | Midostaurin (as Rydapt) is a multitarget kinase inhibitor for the treatment for adult patients with newly diagnosed acute myeloid leukemia (AML) who have a specific genetic mutation called FLT3. It was initially characterized as a potential broad-spectrum antineoplastic agent, with activity toward diverse solid and hem... | Moderate | 1 | [
[
[
1570,
24,
1491
]
],
[
[
1570,
23,
1135
],
[
1135,
62,
1491
]
],
[
[
1570,
23,
112
],
[
112,
23,
1491
]
],
[
[
1570,
24,
888
],
[
888,
... | [
[
[
"Azithromycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Midostaurin"
]
],
[
[
"Azithromycin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Naloxegol"
],
[
... | Azithromycin may cause a minor interaction that can limit clinical effects when taken with Naloxegol and Naloxegol may cause a minor interaction that can limit clinical effects when taken with Midostaurin
Azithromycin may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metron... |
DB00802 | DB08899 | 1,322 | 129 | [
"DDInter43",
"DDInter649"
] | Alfentanil | Enzalutamide | A short-acting opioid anesthetic and analgesic derivative of fentanyl. It produces an early peak analgesic effect and fast recovery of consciousness. Alfentanil is effective as an anesthetic during surgery, for supplementation of analgesia during surgical procedures, and as an analgesic for critically ill patients. | Enzalutamide is an androgen receptor (AR) inhibitor for the treatment of castration-resistant prostate cancer (CRPC), both metastatic and non-metastatic. It is a second-generation antiandrogen agent that the FDA approved on August 31, 2012.[L40639, A252667] Although androgen deprivation therapy (ADT) is the first-line ... | Moderate | 1 | [
[
[
1322,
24,
129
]
],
[
[
1322,
24,
918
],
[
918,
1,
129
]
],
[
[
1322,
6,
8374
],
[
8374,
45,
129
]
],
[
[
1322,
21,
28703
],
[
28703,
... | [
[
[
"Alfentanil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enzalutamide"
]
],
[
[
"Alfentanil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bicalutamide"
],
... | Alfentanil may cause a moderate interaction that could exacerbate diseases when taken with Bicalutamide and Bicalutamide (Compound) resembles Enzalutamide (Compound)
Alfentanil (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Enzalutamide (Compound)
Alfentanil (Compound) causes Pruritus (Side Effect) and Pr... |
DB00603 | DB09046 | 303 | 1,094 | [
"DDInter1137",
"DDInter1201"
] | Medroxyprogesterone acetate | Metreleptin | Medroxyprogesterone acetate (MPA) is a [progesterone] derivative that is more resistant to metabolism for improved pharmacokinetic properties. MPA can be use to treat secondary amenorrhea, endometrial hyperplasia, abnormal uterine bleeding, osteoporosis, vasomotor symptoms in menopause, vulvar and vaginal atrophy, prev... | Metreleptin, a recombinant analog of the human hormone leptin, is an orphan drug used to treat complications of leptin deficiency in people with lipodystrophy. Lipodystrophies include a range of disorders characterized by the reduction, absence, or altered distribution of adipose tissue. Complications of lipodystrophy ... | Moderate | 1 | [
[
[
303,
24,
1094
]
],
[
[
303,
24,
1213
],
[
1213,
24,
1094
]
],
[
[
303,
63,
176
],
[
176,
24,
1094
]
],
[
[
303,
25,
927
],
[
927,
... | [
[
[
"Medroxyprogesterone acetate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metreleptin"
]
],
[
[
"Medroxyprogesterone acetate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",... | Medroxyprogesterone acetate may cause a moderate interaction that could exacerbate diseases when taken with Dasatinib and Dasatinib may cause a moderate interaction that could exacerbate diseases when taken with Metreleptin
Medroxyprogesterone acetate may cause a moderate interaction that could exacerbate diseases when... |
DB01124 | DB08870 | 1,411 | 850 | [
"DDInter1828",
"DDInter228"
] | Tolbutamide | Brentuximab vedotin | Tolbutamide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It is structurally similar to acetohexamide, chlorpropamide and tolazamide and belongs to the sulfonylurea class of insulin secretagogues, which act by stimulating β cells of the pancreas to release... | Brentuximab vedotin, also known as Adcetris®, is an antibody-drug conjugate that combines an anti-CD30 antibody with the drug monomethyl auristatin E (MMAE). It is an anti-neoplastic agent used in the treatment of Hodgkin's lymphoma and systemic anaplastic large-cell lymphoma. Brentuximab vedotin was initially approved... | Moderate | 1 | [
[
[
1411,
24,
850
]
],
[
[
1411,
63,
1338
],
[
1338,
24,
850
]
],
[
[
1411,
24,
1033
],
[
1033,
63,
850
]
],
[
[
1411,
1,
245
],
[
245,
... | [
[
[
"Tolbutamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brentuximab vedotin"
]
],
[
[
"Tolbutamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Meclofenamic aci... | Tolbutamide may cause a moderate interaction that could exacerbate diseases when taken with Meclofenamic acid and Meclofenamic acid may cause a moderate interaction that could exacerbate diseases when taken with Brentuximab vedotin
Tolbutamide may cause a moderate interaction that could exacerbate diseases when taken w... |
DB00175 | DB06317 | 681 | 1,626 | [
"DDInter1509",
"DDInter630"
] | Pravastatin | Elotuzumab | Pravastatin is the 6-alpha-hydroxy acid form of [mevastatin]. Pravastatin was firstly approved in 1991 becoming the second available statin in the United States. It was the first statin administered as the active form and not as a prodrug. This drug was developed by Sankyo Co. Ltd.; however, the first approved pravasta... | Elotuzumab is a humanized IgG1 (Immunoglobulin G) monoclonal antibody indicated in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received one to three prior therapies. Elotuzumab targets SLAMF7, also known as Signaling Lymphocytic Activation Molecule Family... | Moderate | 1 | [
[
[
681,
24,
1626
]
],
[
[
681,
24,
973
],
[
973,
24,
1626
]
],
[
[
681,
1,
1463
],
[
1463,
24,
1626
]
],
[
[
681,
24,
310
],
[
310,
... | [
[
[
"Pravastatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Elotuzumab"
]
],
[
[
"Pravastatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Paclitaxel"
],
[
... | Pravastatin may cause a moderate interaction that could exacerbate diseases when taken with Paclitaxel and Paclitaxel may cause a moderate interaction that could exacerbate diseases when taken with Elotuzumab
Pravastatin (Compound) resembles Lovastatin (Compound) and Lovastatin may cause a moderate interaction that cou... |
DB00196 | DB01035 | 600 | 1,401 | [
"DDInter743",
"DDInter1524"
] | Fluconazole | Procainamide | Fluconazole, commonly known as _Diflucan_, is an antifungal drug used for the treatment of both systemic and superficial fungal infections in a variety of tissues. It was initially approved by the FDA in 1990. This drug is an _azole_ antifungal, in the same drug family as [ketoconazole] and [itraconazole]. Fluconazole ... | A derivative of procaine with less CNS action. | Major | 2 | [
[
[
600,
25,
1401
]
],
[
[
600,
21,
28658
],
[
28658,
60,
1401
]
],
[
[
600,
23,
112
],
[
112,
23,
1401
]
],
[
[
600,
24,
770
],
[
770,
... | [
[
[
"Fluconazole",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Procainamide"
]
],
[
[
"Fluconazole",
"{u} (Compound) causes {v} (Side Effect)",
"Vomiting"
],
[
"Vomiting",
"{u} (Side Effect) is caused by {v} (Co... | Fluconazole (Compound) causes Vomiting (Side Effect) and Vomiting (Side Effect) is caused by Procainamide (Compound)
Fluconazole may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Pro... |
DB00983 | DB01364 | 480 | 22 | [
"DDInter776",
"DDInter650"
] | Formoterol | Ephedrine | Formoterol is an inhaled beta<sub>2</sub>-agonist used in the management of COPD and asthma that was first approved for use in the United States in 2001. It acts on bronchial smooth muscle to dilate and relax airways, and is administered as a racemic mixture of its active (R;R)- and inactive (S;S)-enantiomers. A major ... | Ephedrine was first described in western literature in 1888, as a naturally occurring component of the ephedra plant, along with [pseudoephedrine]. Ephedrine acts as both a direct and indirect sympathomimetic. It is an alpha- and beta-adrenergic receptor agonist; however, it also causes the indirect release of norepine... | Moderate | 1 | [
[
[
480,
24,
22
]
],
[
[
480,
63,
80
],
[
80,
24,
22
]
],
[
[
480,
24,
1529
],
[
1529,
63,
22
]
],
[
[
480,
24,
280
],
[
280,
1,
... | [
[
[
"Formoterol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ephedrine"
]
],
[
[
"Formoterol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Amphetamine"
],
[
... | Formoterol may cause a moderate interaction that could exacerbate diseases when taken with Amphetamine and Amphetamine may cause a moderate interaction that could exacerbate diseases when taken with Ephedrine
Formoterol may cause a moderate interaction that could exacerbate diseases when taken with Metamfetamine and Me... |
DB00009 | DB00722 | 1,271 | 743 | [
"DDInter56",
"DDInter1079"
] | Alteplase | Lisinopril | Alteplase is a recombinant tissue plasminogen activator (rt-PA) used as a thrombolytic agent. It cleaves plasminogen to form plasmin, an enzyme involved in the degradation of fibrin clots. In the absence of fibrin, the alteplase-mediated conversion of plasminogen is limited, thanks to the high affinity between alteplas... | Lisinopril is an angiotensin converting enzyme inhibitor (ACEI) used to treat hypertension, heart failure, and myocardial infarction.[L8384,L8387,L8390] Lisinopril and [captopril] are the only ACEIs that are not prodrugs. It functions by inhibition of angiotensin converting enzyme as well as the renin angiotensin aldos... | Moderate | 1 | [
[
[
1271,
24,
743
]
],
[
[
1271,
24,
610
],
[
610,
40,
743
]
],
[
[
1271,
24,
1638
],
[
1638,
1,
743
]
],
[
[
1271,
25,
500
],
[
500,
... | [
[
[
"Alteplase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lisinopril"
]
],
[
[
"Alteplase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enalapril"
],
[
... | Alteplase may cause a moderate interaction that could exacerbate diseases when taken with Enalapril and Enalapril (Compound) resembles Lisinopril (Compound)
Alteplase may cause a moderate interaction that could exacerbate diseases when taken with Trandolapril and Trandolapril (Compound) resembles Lisinopril (Compound)
... |
DB00783 | DB09038 | 1,438 | 1,450 | [
"DDInter679",
"DDInter636"
] | Estradiol | Empagliflozin | Estradiol is a naturally occurring hormone circulating endogenously in females. It is commercially available in several hormone therapy products for managing conditions associated with reduced estrogen, such as vulvovaginal atrophy and hot flashes. Some available forms of estradiol include oral tablets, injections, vag... | Empagliflozin is an inhibitor of sodium-glucose co-transporter-2 (SGLT2), the transporters primarily responsible for the reabsorption of glucose in the kidney. It is used clinically as an adjunct to diet and exercise, often in combination with other drug therapies,[L13673,L13679,L11479] for the management of type 2 dia... | Moderate | 1 | [
[
[
1438,
24,
1450
]
],
[
[
1438,
24,
1486
],
[
1486,
24,
1450
]
],
[
[
1438,
63,
1179
],
[
1179,
24,
1450
]
],
[
[
1438,
24,
1017
],
[
10... | [
[
[
"Estradiol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Empagliflozin"
]
],
[
[
"Estradiol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methylprednisolone"
],... | Estradiol may cause a moderate interaction that could exacerbate diseases when taken with Methylprednisolone and Methylprednisolone may cause a moderate interaction that could exacerbate diseases when taken with Empagliflozin
Estradiol may cause a moderate interaction that could exacerbate diseases when taken with Insu... |
DB00342 | DB08875 | 1,181 | 1,618 | [
"DDInter1770",
"DDInter262"
] | Terfenadine | Cabozantinib | In the U.S., Terfenadine was superseded by fexofenadine in the 1990s due to the risk of cardiac arrhythmia caused by QT interval prolongation. | Cabozantinib was first approved in 2012 and is a non-specific tyrosine kinase inhibitor. It was initially approved in the US under the brand name Cometriq, which is indicated for the treatment of metastatic medullary thyroid cancer. In 2016, a capsule formulation (Cabometyx) was approved for the treatment of advanced r... | Major | 2 | [
[
[
1181,
25,
1618
]
],
[
[
1181,
23,
112
],
[
112,
23,
1618
]
],
[
[
1181,
25,
723
],
[
723,
24,
1618
]
],
[
[
1181,
24,
384
],
[
384,
... | [
[
[
"Terfenadine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cabozantinib"
]
],
[
[
"Terfenadine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metro... | Terfenadine may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Cabozantinib
Terfenadine may lead to a major life threatening interaction when taken with Aprepitant and Aprepitant may ... |
DB00627 | DB00945 | 265 | 1,479 | [
"DDInter1286",
"DDInter20"
] | Niacin | Acetylsalicylic acid | Niacin is a B vitamin used to treat vitamin deficiencies as well as hyperlipidemia, dyslipidemia, hypertriglyceridemia, and to reduce the risk of myocardial infarctions.[L7550,L7553,L7556,L7559,L7562,L7565] | Also known as _Aspirin_, acetylsalicylic acid (ASA) is a commonly used drug for the treatment of pain and fever due to various causes. Acetylsalicylic acid has both anti-inflammatory and antipyretic effects. This drug also inhibits platelet aggregation and is used in the prevention of blood clots stroke, and myocardial... | Minor | 0 | [
[
[
265,
23,
1479
]
],
[
[
265,
40,
11404
],
[
11404,
40,
1479
]
],
[
[
265,
5,
11576
],
[
11576,
44,
1479
]
],
[
[
265,
21,
28931
],
[
28... | [
[
[
"Niacin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Acetylsalicylic acid"
]
],
[
[
"Niacin",
"{u} (Compound) resembles {v} (Compound)",
"Salicylic acid"
],
[
"Salicylic acid",
"{u} (Compound) ... | Niacin (Compound) resembles Salicylic acid (Compound) and Salicylic acid (Compound) resembles Acetylsalicylic acid (Compound)
Niacin (Compound) treats coronary artery disease (Disease) and coronary artery disease (Disease) is treated by Acetylsalicylic acid (Compound)
Niacin (Compound) causes Haemorrhage (Side Effect) ... |
DB01001 | DB14754 | 688 | 1,663 | [
"DDInter1632",
"DDInter1697"
] | Salbutamol | Solriamfetol | Salbutamol is a short-acting, selective beta2-adrenergic receptor agonist used in the treatment of asthma and COPD. It is 29 times more selective for beta2 receptors than beta1 receptors giving it higher specificity for pulmonary beta receptors versus beta1-adrenergic receptors located in the heart. Salbutamol is formu... | Solriamfetol marketed under the brand name Sunosi by Jazz Pharmaceuticals in the United States is a dopamine and norepinephrine reuptake inhibitor (DNRI) indicated in treating daytime sleepiness associated with narcolepsy or obstructive sleep apnea[FDA Label]. Solriamfetol was given FDA approval in 2019[FDA Label]. | Moderate | 1 | [
[
[
688,
24,
1663
]
],
[
[
688,
63,
1674
],
[
1674,
24,
1663
]
],
[
[
688,
24,
1148
],
[
1148,
24,
1663
]
],
[
[
688,
24,
1053
],
[
1053,
... | [
[
[
"Salbutamol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Solriamfetol"
]
],
[
[
"Salbutamol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Orciprenaline"
],
... | Salbutamol may cause a moderate interaction that could exacerbate diseases when taken with Orciprenaline and Orciprenaline may cause a moderate interaction that could exacerbate diseases when taken with Solriamfetol
Salbutamol may cause a moderate interaction that could exacerbate diseases when taken with Isoprenaline ... |
DB00055 | DB14006 | 834 | 972 | [
"DDInter605",
"DDInter370"
] | Drotrecogin alfa | Choline salicylate | Drotrecogin alfa is activated human protein C that is synthesized by recombinant DNA technology. It is a glycoprotein of approximately 55 kilodalton molecular weight, consisting of a heavy chain and a light chain linked by a disulfide bond. Drotrecogin alfa was withdrawn from the market after a major study indicated th... | Choline salicylate is an anti-inflammatory pain reliever agent that is related to aspirin. It is used to decrease swelling and to treat mild-moderate pain. It is used to treat arthritis in both children and adults. This medicine can also be used for fever . Choline Salicylate is the choline salt of salicylic acid, used... | Moderate | 1 | [
[
[
834,
24,
972
]
],
[
[
834,
25,
553
],
[
553,
24,
972
]
],
[
[
834,
64,
1255
],
[
1255,
24,
972
]
],
[
[
834,
24,
1039
],
[
1039,
... | [
[
[
"Drotrecogin alfa",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Choline salicylate"
]
],
[
[
"Drotrecogin alfa",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fondaparinux"
],
... | Drotrecogin alfa may lead to a major life threatening interaction when taken with Fondaparinux and Fondaparinux may cause a moderate interaction that could exacerbate diseases when taken with Choline salicylate
Drotrecogin alfa may lead to a major life threatening interaction when taken with Urokinase and Urokinase may... |
DB00443 | DB12887 | 251 | 1,598 | [
"DDInter195",
"DDInter1750"
] | Betamethasone | Tazemetostat | Betamethasone is a long-acting corticosteroid with immunosuppressive and antiinflammatory properties. It can be used topically to manage inflammatory skin conditions such as eczema, and parenterally to manage several disease states including autoimmune disorders. Betamethasone has potent glucocorticoid activity and neg... | Tazemetostat is a methyltransferase inhibitor used to treat metastatic or locally advanced epithelioid sarcoma not eligible for complete resection. Tazemetostat was first named in literature as EPZ-6438. Tazemetaostat was granted FDA approval on 23 January 2020. | Moderate | 1 | [
[
[
251,
24,
1598
]
],
[
[
251,
63,
1324
],
[
1324,
24,
1598
]
],
[
[
251,
1,
891
],
[
891,
24,
1598
]
],
[
[
251,
40,
870
],
[
870,
... | [
[
[
"Betamethasone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tazemetostat"
]
],
[
[
"Betamethasone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Troglitazone"
]... | Betamethasone may cause a moderate interaction that could exacerbate diseases when taken with Troglitazone and Troglitazone may cause a moderate interaction that could exacerbate diseases when taken with Tazemetostat
Betamethasone (Compound) resembles Prednisolone (Compound) and Prednisolone may cause a moderate intera... |
DB01591 | DB06595 | 667 | 1,491 | [
"DDInter1696",
"DDInter1214"
] | Solifenacin | Midostaurin | Solifenacin is a competitive muscarinic receptor antagonist indicated to treat an overactive bladder with urinary incontinence, urgency, and frequency. It has a long duration of action as it is usually taken once daily. Solifenacin was granted FDA approval on 19 November 2004. | Midostaurin (as Rydapt) is a multitarget kinase inhibitor for the treatment for adult patients with newly diagnosed acute myeloid leukemia (AML) who have a specific genetic mutation called FLT3. It was initially characterized as a potential broad-spectrum antineoplastic agent, with activity toward diverse solid and hem... | Moderate | 1 | [
[
[
667,
24,
1491
]
],
[
[
667,
62,
112
],
[
112,
23,
1491
]
],
[
[
667,
63,
888
],
[
888,
24,
1491
]
],
[
[
667,
24,
1017
],
[
1017,
... | [
[
[
"Solifenacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Midostaurin"
]
],
[
[
"Solifenacin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
... | Solifenacin may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Midostaurin
Solifenacin may cause a moderate interaction that could exacerbate diseases when taken with Tamoxifen and Ta... |
DB00238 | DB00530 | 188 | 1,195 | [
"DDInter1285",
"DDInter667"
] | Nevirapine | Erlotinib | A potent, non-nucleoside reverse transcriptase inhibitor (NNRTI) used in combination with nucleoside analogues for treatment of Human Immunodeficiency Virus Type 1 (HIV-1) infection and AIDS. Structurally, nevirapine belongs to the dipyridodiazepinone chemical class. | Erlotinib is an inhibitor of the epidermal growth factor receptor (EGFR) tyrosine kinase that is used in the treatment of non-small cell lung cancer, pancreatic cancer and several other types of cancer. It is typically marketed under the trade name Tarceva. Erlotinib binds to the epidermal growth factor receptor (EGFR)... | Moderate | 1 | [
[
[
188,
24,
1195
]
],
[
[
188,
24,
1069
],
[
1069,
1,
1195
]
],
[
[
188,
24,
883
],
[
883,
40,
1195
]
],
[
[
188,
6,
7950
],
[
7950,
... | [
[
[
"Nevirapine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Erlotinib"
]
],
[
[
"Nevirapine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vandetanib"
],
[
... | Nevirapine may cause a moderate interaction that could exacerbate diseases when taken with Vandetanib and Vandetanib (Compound) resembles Erlotinib (Compound)
Nevirapine may cause a moderate interaction that could exacerbate diseases when taken with Gefitinib and Gefitinib (Compound) resembles Erlotinib (Compound)
Nevi... |
DB00399 | DB00795 | 963 | 50 | [
"DDInter1968",
"DDInter1725"
] | Zoledronic acid | Sulfasalazine | Zoledronic acid, or CGP 42'446, is a third generation, nitrogen containing bisphosphonate similar to [ibandronic acid], [minodronic acid], and [risedronic acid]. Zoledronic acid is used to treat and prevent multiple forms of osteoporosis, hypercalcemia of malignancy, multiple myeloma, bone metastases from solid tumors,... | Sulfasalazine is an anti-inflammatory drug structurally related to salicylates and other non-steroidal anti-inflammatory drugs. It is indicated for managing inflammatory diseases such as ulcerative colitis and rheumatoid arthritis (RA).[L39065, A255582] Metabolized by intestinal bacteria, sulfasalazine is broken down i... | Moderate | 1 | [
[
[
963,
24,
50
]
],
[
[
963,
24,
712
],
[
712,
1,
50
]
],
[
[
963,
24,
1481
],
[
1481,
24,
50
]
],
[
[
963,
40,
641
],
[
641,
24,
... | [
[
[
"Zoledronic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sulfasalazine"
]
],
[
[
"Zoledronic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Olsalazine"
... | Zoledronic acid may cause a moderate interaction that could exacerbate diseases when taken with Olsalazine and Olsalazine (Compound) resembles Sulfasalazine (Compound)
Zoledronic acid may cause a moderate interaction that could exacerbate diseases when taken with Polymyxin B and Polymyxin B may cause a moderate interac... |
DB00738 | DB08826 | 485 | 1,292 | [
"DDInter1420",
"DDInter489"
] | Pentamidine | Deferiprone | Antiprotozoal agent effective in trypanosomiasis, leishmaniasis, and some fungal infections; used in treatment of pneumocystis pneumonia in HIV-infected patients. It may cause diabetes mellitus, central nervous system damage, and other toxic effects. | Deferiprone is an oral iron chelator used as a second line agent in thalassemia syndromes when iron overload from blood transfusions occurs. Thalassemias are a type of hereditary anaemia due a defect in the production of hemoglobin. As a result, erythropoiesis, the production of new red blood cells, is impaired. FDA ap... | Major | 2 | [
[
[
485,
25,
1292
]
],
[
[
485,
21,
28809
],
[
28809,
60,
1292
]
],
[
[
485,
25,
45
],
[
45,
24,
1292
]
],
[
[
485,
24,
603
],
[
603,
... | [
[
[
"Pentamidine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Deferiprone"
]
],
[
[
"Pentamidine",
"{u} (Compound) causes {v} (Side Effect)",
"Diarrhoea"
],
[
"Diarrhoea",
"{u} (Side Effect) is caused by {v} (C... | Pentamidine (Compound) causes Diarrhoea (Side Effect) and Diarrhoea (Side Effect) is caused by Deferiprone (Compound)
Pentamidine may lead to a major life threatening interaction when taken with Didanosine and Didanosine may cause a moderate interaction that could exacerbate diseases when taken with Deferiprone
Pentami... |
DB00373 | DB00651 | 461 | 746 | [
"DDInter1809",
"DDInter613"
] | Timolol | Dyphylline | Timolol is a nonselective beta-adrenergic antagonist given in an eye drop solution to reduce intraocular pressure, or pressure in the eyes. It is also used in tablet form as a drug to treat hypertension. Timolol was first approved by the FDA in 1978. This drug is marketed by several manufacturers and is an effective ag... | Dyphylline is a theophylline derivative with broncho- and vasodilator properties. It is typically used in the management of asthma, cardiac dyspnea, and bronchitis. | Major | 2 | [
[
[
461,
25,
746
]
],
[
[
461,
64,
1031
],
[
1031,
1,
746
]
],
[
[
461,
21,
28642
],
[
28642,
60,
746
]
],
[
[
461,
24,
22
],
[
22,
... | [
[
[
"Timolol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dyphylline"
]
],
[
[
"Timolol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Theophylline"
],
[
"Theophylline",
"{u} (Co... | Timolol may lead to a major life threatening interaction when taken with Theophylline and Theophylline (Compound) resembles Dyphylline (Compound)
Timolol (Compound) causes Shock (Side Effect) and Shock (Side Effect) is caused by Dyphylline (Compound)
Timolol may cause a moderate interaction that could exacerbate diseas... |
DB00526 | DB01236 | 1,555 | 679 | [
"DDInter1355",
"DDInter1664"
] | Oxaliplatin | Sevoflurane | Oxaliplatin is a platinum-based chemotherapy drug in the same family as cisplatin and carboplatin. Compared to cisplatin the two amine groups are replaced by diamino cyclohexane (DACH) group to provide a greater antitumor effect. However, this leads to poorer water solubility, which was compensated by the addition of t... | Sevoflurane is an ether inhalation anesthetic agent used to induce and maintain general anesthesia. It is a volatile, non-flammable compound with a low solubility profile and blood/gas partition coefficient. Sevoflurane was patented in 1972, was approved for clinical use in Japan in 1990, and approved by the FDA in 199... | Moderate | 1 | [
[
[
1555,
24,
679
]
],
[
[
1555,
24,
1262
],
[
1262,
40,
679
]
],
[
[
1555,
6,
6365
],
[
6365,
45,
679
]
],
[
[
1555,
24,
112
],
[
112,
... | [
[
[
"Oxaliplatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sevoflurane"
]
],
[
[
"Oxaliplatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Perflutren"
],
[... | Oxaliplatin may cause a moderate interaction that could exacerbate diseases when taken with Perflutren and Perflutren (Compound) resembles Sevoflurane (Compound)
Oxaliplatin (Compound) binds CYP2E1 (Gene) and CYP2E1 (Gene) is bound by Sevoflurane (Compound)
Oxaliplatin may cause a moderate interaction that could exacer... |
DB01041 | DB08880 | 770 | 1,510 | [
"DDInter1789",
"DDInter1771"
] | Thalidomide | Teriflunomide | A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, thalidomide was withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of inflammatory disorders and cancers. Thalidomide displays immunosuppressive and anti-angiogenic activity through modulating ... | Teriflunomide is the active metabolite of leflunomide, and it acts as an immunomodulatory agent by inhibiting pyrimidine synthesis. It is marketed under the name Aubagio® and is indicated for the treatment of multiple sclerosis, specifically relapsing forms. The FDA label states an important warning about the risk of h... | Major | 2 | [
[
[
770,
25,
1510
]
],
[
[
770,
24,
129
],
[
129,
63,
1510
]
],
[
[
770,
24,
1136
],
[
1136,
24,
1510
]
],
[
[
770,
63,
563
],
[
563,
... | [
[
[
"Thalidomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Teriflunomide"
]
],
[
[
"Thalidomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enzalutamide"
],
[
"Enz... | Thalidomide may cause a moderate interaction that could exacerbate diseases when taken with Enzalutamide and Enzalutamide may cause a moderate interaction that could exacerbate diseases when taken with Teriflunomide
Thalidomide may cause a moderate interaction that could exacerbate diseases when taken with Denosumab an... |
DB00902 | DB01043 | 104 | 108 | [
"DDInter1168",
"DDInter1146"
] | Methdilazine | Memantine | Methdilazine is a phenothiazine compound with antihistaminic activity. It is used in the treatment of various dermatoses to relieve pruritus. | Initially approved by the FDA in 2013, memantine is an N-methyl-D-aspartate (NMDA) receptor antagonist used in the management of Alzheimer's Disease (AD). It is different from many other Alzheimer's Disease medications, as it works by a different mechanism than the cholinesterase enzyme inhibitors normally employed in ... | Moderate | 1 | [
[
[
104,
24,
108
]
],
[
[
104,
63,
1645
],
[
1645,
23,
108
]
],
[
[
104,
24,
1264
],
[
1264,
63,
108
]
],
[
[
104,
24,
1192
],
[
1192,
... | [
[
[
"Methdilazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Memantine"
]
],
[
[
"Methdilazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metformin"
],
[
... | Methdilazine may cause a moderate interaction that could exacerbate diseases when taken with Metformin and Metformin may cause a minor interaction that can limit clinical effects when taken with Memantine
Methdilazine may cause a moderate interaction that could exacerbate diseases when taken with Doxepin and Doxepin ma... |
DB01114 | DB06077 | 272 | 879 | [
"DDInter362",
"DDInter1102"
] | Chlorpheniramine | Lumateperone | A histamine H1 antagonist used in allergic reactions, hay fever, rhinitis, urticaria, and asthma. It has also been used in veterinary applications. One of the most widely used of the classical antihistaminics, it generally causes less drowsiness and sedation than promethazine. | Schizophrenia is a complex mental illness and impacts approximately 1% of the population. Although there are several antipsychotics including [aripiprazole], [paliperidone] and [clozapine] available for clinical use, they are generally accompanied by significant metabolic and/or neurological adverse effects. Lumatepero... | Moderate | 1 | [
[
[
272,
24,
879
]
],
[
[
272,
24,
1374
],
[
1374,
24,
879
]
],
[
[
272,
24,
407
],
[
407,
63,
879
]
],
[
[
272,
63,
999
],
[
999,
2... | [
[
[
"Chlorpheniramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lumateperone"
]
],
[
[
"Chlorpheniramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Abiraterone"
... | Chlorpheniramine may cause a moderate interaction that could exacerbate diseases when taken with Abiraterone and Abiraterone may cause a moderate interaction that could exacerbate diseases when taken with Lumateperone
Chlorpheniramine may cause a moderate interaction that could exacerbate diseases when taken with Opium... |
DB01242 | DB09030 | 1,237 | 840 | [
"DDInter410",
"DDInter1945"
] | Clomipramine | Vorapaxar | Clomipramine, the 3-chloro analog of imipramine, is a dibenzazepine-derivative tricyclic antidepressant (TCA). TCAs are structurally similar to phenothiazines. They contain a tricyclic ring system with an alkyl amine substituent on the central ring. In non-depressed individuals, clomipramine does not affect mood or aro... | Vorapaxar is a tricyclic himbacine-derived selective inhibitor of protease activated receptor (PAR-1) indicated for reducing the incidence of thrombotic cardiovascular events in patients with a history of myocardial infarction (MI) or with peripheral arterial disease (PAD). By inhibiting PAR-1, a thrombin receptor expr... | Moderate | 1 | [
[
[
1237,
24,
840
]
],
[
[
1237,
63,
885
],
[
885,
24,
840
]
],
[
[
1237,
64,
1039
],
[
1039,
24,
840
]
],
[
[
1237,
24,
578
],
[
578,
... | [
[
[
"Clomipramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vorapaxar"
]
],
[
[
"Clomipramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Epoprostenol"
],
... | Clomipramine may cause a moderate interaction that could exacerbate diseases when taken with Epoprostenol and Epoprostenol may cause a moderate interaction that could exacerbate diseases when taken with Vorapaxar
Clomipramine may lead to a major life threatening interaction when taken with Dexfenfluramine and Dexfenflu... |
DB01015 | DB11730 | 1,247 | 351 | [
"DDInter1724",
"DDInter1588"
] | Sulfamethoxazole | Ribociclib | Sulfamethoxazole is a bacteriostatic sulfonamide antibiotic that interferes with folic acid synthesis in susceptible bacteria. It is generally given in combination with [trimethoprim], which inhibits a sequential step in bacterial folic acid synthesis - these agents work synergistically to block two consecutive steps i... | Ribociclib is a selective cyclin-dependent kinase inhibitor, a class of drugs that help slow the progression of cancer by inhibiting two proteins called cyclin-dependent kinase 4 and 6 (CDK4/6). These proteins, when over-activated, can enable cancer cells to grow and divide too quickly. Targeting CDK4/6 with enhanced p... | Minor | 0 | [
[
[
1247,
23,
351
]
],
[
[
1247,
62,
112
],
[
112,
23,
351
]
],
[
[
1247,
63,
372
],
[
372,
24,
351
]
],
[
[
1247,
24,
1613
],
[
1613,
... | [
[
[
"Sulfamethoxazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Ribociclib"
]
],
[
[
"Sulfamethoxazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
... | Sulfamethoxazole may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Ribociclib
Sulfamethoxazole may cause a moderate interaction that could exacerbate diseases when taken with Clofara... |
DB00641 | DB00776 | 467 | 1,335 | [
"DDInter1675",
"DDInter1360"
] | Simvastatin | Oxcarbazepine | Simvastatin, also known as the brand name product Zocor, is a lipid-lowering drug derived synthetically from a fermentation product of _Aspergillus terreus_. It belongs to the statin class of medications, which are used to lower the risk of cardiovascular disease and manage abnormal lipid levels by inhibiting the endog... | Oxcarbazepine is an anti-epileptic medication used in the treatment of partial onset seizures that was first approved for use in the United States in 2000.[L8627,L8630,L8633] It is a structural derivative of [carbamazepine] and exerts a majority of its activity via a pharmacologically active metabolite, MHD, which exis... | Moderate | 1 | [
[
[
467,
24,
1335
]
],
[
[
467,
23,
126
],
[
126,
1,
1335
]
],
[
[
467,
63,
1236
],
[
1236,
1,
1335
]
],
[
[
467,
24,
307
],
[
307,
... | [
[
[
"Simvastatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Oxcarbazepine"
]
],
[
[
"Simvastatin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Warfarin"
],
[
... | Simvastatin may cause a minor interaction that can limit clinical effects when taken with Warfarin and Warfarin (Compound) resembles Oxcarbazepine (Compound)
Simvastatin may cause a moderate interaction that could exacerbate diseases when taken with Carbamazepine and Carbamazepine (Compound) resembles Oxcarbazepine (Co... |
DB00352 | DB11627 | 482 | 1,367 | [
"DDInter1814",
"DDInter860"
] | Tioguanine | Hepatitis B Vaccine (Recombinant) | An antineoplastic compound which also has antimetabolite action. The drug is used in the therapy of acute leukemia. | Hepatitis B Vaccine is an ingredient in the EMA-withdrawn product Quintanrix. It is marketed in Canada as Engerix B. It is also a part of Twinrix (Hep A/Hep B vaccine) available also in Canada. The hepatitis B virus induces a severe form of viral hepatitis. Other causative agents are hepatitis A virus, and the non-A, n... | Moderate | 1 | [
[
[
482,
24,
1367
]
],
[
[
482,
63,
1648
],
[
1648,
24,
1367
]
],
[
[
482,
64,
1064
],
[
1064,
24,
1367
]
],
[
[
482,
24,
1480
],
[
1480,
... | [
[
[
"Tioguanine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hepatitis B Vaccine (Recombinant)"
]
],
[
[
"Tioguanine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alde... | Tioguanine may cause a moderate interaction that could exacerbate diseases when taken with Aldesleukin and Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Hepatitis B Vaccine (Recombinant)
Tioguanine may lead to a major life threatening interaction when taken with Cladribine ... |
DB01064 | DB14881 | 1,148 | 180 | [
"DDInter987",
"DDInter1329"
] | Isoprenaline | Oliceridine | Isoprenaline is a non-selective beta adrenergic receptor agonist indicated to treat heart block, Adams-Stokes attacks, bronchospasm in anesthesia, cadiac arrest, hypovolemic shocks, septic shock, hypoperfusion, congestive hear failure, and cardiogenic shock.[A15638,L33160] Isoprenaline research in the 1940s found that ... | Severe acute pain occurs through nociceptive signalling involving both ascending and descending spinal pathways, in which nerve conductance is mediated in part by the action of opioid receptors.[A218041, A218046] Opioid receptors are seven-transmembrane G-protein-coupled receptors (GPCRs), of which the μ-opioid recepto... | Moderate | 1 | [
[
[
1148,
24,
180
]
],
[
[
1148,
24,
401
],
[
401,
24,
180
]
],
[
[
1148,
63,
618
],
[
618,
24,
180
]
],
[
[
1148,
74,
1674
],
[
1674,
... | [
[
[
"Isoprenaline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Oliceridine"
]
],
[
[
"Isoprenaline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Promethazine"
],
... | Isoprenaline may cause a moderate interaction that could exacerbate diseases when taken with Promethazine and Promethazine may cause a moderate interaction that could exacerbate diseases when taken with Oliceridine
Isoprenaline may cause a moderate interaction that could exacerbate diseases when taken with Abarelix and... |
DB00357 | DB09034 | 1,051 | 1,313 | [
"DDInter71",
"DDInter1733"
] | Aminoglutethimide | Suvorexant | An aromatase inhibitor that produces a state of "medical" adrenalectomy by blocking the production of adrenal steroids. It also blocks the conversion of androgens to estrogens. Aminoglutethimide has been used in the treatment of advanced breast and prostate cancer. It was formerly used for its weak anticonvulsant prope... | Suvorexant is a selective dual antagonist of orexin receptors OX1R and OX2R that promotes sleep by reducing wakefulness and arousal. It has been approved for the treatment of insomnia. | Moderate | 1 | [
[
[
1051,
24,
1313
]
],
[
[
1051,
24,
1135
],
[
1135,
62,
1313
]
],
[
[
1051,
24,
1213
],
[
1213,
24,
1313
]
],
[
[
1051,
24,
1362
],
[
13... | [
[
[
"Aminoglutethimide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Suvorexant"
]
],
[
[
"Aminoglutethimide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Naloxegol"
... | Aminoglutethimide may cause a moderate interaction that could exacerbate diseases when taken with Naloxegol and Naloxegol may cause a minor interaction that can limit clinical effects when taken with Suvorexant
Aminoglutethimide may cause a moderate interaction that could exacerbate diseases when taken with Dasatinib a... |
DB00352 | DB09122 | 482 | 1,613 | [
"DDInter1814",
"DDInter1409"
] | Tioguanine | Peginterferon beta-1a | An antineoplastic compound which also has antimetabolite action. The drug is used in the therapy of acute leukemia. | Multiple Sclerosis (MS) is a chronic and inflammatory autoimmune disease of the central nervous system, disrupting communication between the brain and other parts of the body. Most patients diagnosed with this illness experience their initial disease symptoms between the age of 20 to 40, often the most productive years... | Moderate | 1 | [
[
[
482,
24,
1613
]
],
[
[
482,
24,
671
],
[
671,
24,
1613
]
],
[
[
482,
24,
975
],
[
975,
63,
1613
]
],
[
[
482,
63,
600
],
[
600,
... | [
[
[
"Tioguanine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Peginterferon beta-1a"
]
],
[
[
"Tioguanine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fluvastatin"
... | Tioguanine may cause a moderate interaction that could exacerbate diseases when taken with Fluvastatin and Fluvastatin may cause a moderate interaction that could exacerbate diseases when taken with Peginterferon beta-1a
Tioguanine may cause a moderate interaction that could exacerbate diseases when taken with Lurbinec... |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.